US20130209543A1 - Enhanced treatment regimens using mtor inhibitors - Google Patents

Enhanced treatment regimens using mtor inhibitors Download PDF

Info

Publication number
US20130209543A1
US20130209543A1 US13/683,967 US201213683967A US2013209543A1 US 20130209543 A1 US20130209543 A1 US 20130209543A1 US 201213683967 A US201213683967 A US 201213683967A US 2013209543 A1 US2013209543 A1 US 2013209543A1
Authority
US
United States
Prior art keywords
alkyl
aryl
alkynyl
alkenyl
mtorc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/683,967
Other languages
English (en)
Inventor
Yi Liu
Lynne Bui
Michael Martin
Troy Edward Wilson
Christian Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellikine LLC
Faeth Therapeutics Inc
Original Assignee
Intellikine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellikine LLC filed Critical Intellikine LLC
Priority to US13/683,967 priority Critical patent/US20130209543A1/en
Assigned to INTELLIKINE LLC reassignment INTELLIKINE LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, YI, BUI, Lynne, WILSON, TROY EDWARD, ROMMEL, CHRISTIAN, MARTIN, MICHAEL
Publication of US20130209543A1 publication Critical patent/US20130209543A1/en
Assigned to CALITHERA BIOSCIENCES, INC. reassignment CALITHERA BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Assigned to FAETH THERAPEUTICS, INC. reassignment FAETH THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CALITHERA BIOSCIENCES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the activity of cells can be regulated by external signals that stimulate or inhibit intracellular events.
  • the process by which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response is referred to as signal transduction.
  • cascades of signal transduction events have been elucidated and found to play a central role in a variety of biological responses. Defects in various components of signal transduction pathways have been found to account for a vast number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases (Gaestel et al. Current Medicinal Chemistry (2007) 14:2214-2234).
  • Kinases represent a class of important signaling molecules. Kinases can generally be classified into protein kinases and lipid kinases, and certain kinases exhibit dual specificities. Protein kinases are enzymes that phosphorylate other proteins and/or themselves (i.e., autophosphorylation).
  • Protein kinases can be generally classified into three major groups based upon their substrate utilization: tyrosine kinases which predominantly phosphorylate substrates on tyrosine residues (e.g., erb2, PDGF receptor, EGF receptor, VEGF receptor, src, abl), serine/threonine kinases which predominantly phosphorylate substrates on serine and/or threonine residues (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, Akt), and dual-specificity kinases which phosphorylate substrates on tyrosine, serine and/or threonine residues.
  • tyrosine kinases which predominantly phosphorylate substrates on tyrosine residues (e.g., erb2, PDGF receptor, EGF receptor, VEGF receptor, src, abl), serine/threonine kinases which predominantly phosphorylate substrates on
  • Lipid kinases are enzymes that catalyze the phosphorylation of lipids. These enzymes, and the resulting phosphorylated lipids and lipid-derived biologically active organic molecules, play a role in many different physiological processes, including cell proliferation, migration, adhesion, and differentiation. Certain lipid kinases are membrane associated and they catalyze the phosphorylation of lipids contained in or associated with cell membranes. Examples of such enzymes include phosphoinositide(s) kinases (such as PI3-kinases, PI4-Kinases), diacylglycerol kinases, and sphingosine kinases.
  • PI3Ks The phosphoinositide 3-kinases (PI3Ks) signaling pathway is one of the most highly mutated systems in human cancers. PI3K signaling is also a key factor in many other diseases in humans. PI3K signaling is involved in many disease states including allergic contact dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, asthma, disorders related to diabetic complications, and inflammatory complications of the cardiovascular system such as acute coronary syndrome.
  • PI3Ks are members of a unique and conserved family of intracellular lipid kinases that phosphorylate the 3′-OH group on phosphatidylinositols or phosphoinositides.
  • the PI3K family comprises 15 kinases with distinct substrate specificities, expression patterns, and modes of regulation (Katso et al., 2001).
  • the class I PI3Ks (p110 ⁇ , p110 ⁇ , p110 ⁇ , and p110 ⁇ ) are typically activated by tyrosine kinases or G-protein coupled receptors to generate phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ), which engages downstream effectors such as those in the Akt/PDK1 pathway, mTOR, the Tec family kinases, and the Rho family GTPases.
  • the class II and III PI3-Ks play a key role in intracellular trafficking through the synthesis of PI(3)P and PI(3,4)P2.
  • the PIKKs are protein kinases that control cell growth (mTORC1) or monitor genomic integrity (ATM, ATR, DNA-PK, and hSmg-1).
  • PIP 3 initiates potent growth and survival signals.
  • the PI3K pathway is activated by direct genetic mutation.
  • PI3K signaling pathway plays a pivotal role in cell proliferation and differentiation, inhibition of this pathway is believed to be beneficial in hyperproliferative diseases.
  • Downstream mediators of the PI3K signal transduction pathway include Akt and mammalian target of rapamycin (mTOR).
  • Akt possesses a plckstrin homology (PH) domain that bind PIP3, leading to Akt kinase activation.
  • PH plckstrin homology
  • Akt phosphorylates many substrates and is a central downstream effector of PI3K for diverse cellular responses.
  • Full activation of Akt typically requires phosphorylation of T308 in the activation loop and S473 in a hydrophobic motif
  • One important function of Akt is to augment the activity of mTOR, through phosphorylation of TSC2 and other mechanisms.
  • mTOR is a serine-threonine kinase related to the lipid kinases of the PI3K family. mTOR has been implicated in a wide range of biological processes including cell growth, cell proliferation, cell motility and survival. Disregulation of the mTOR pathway has been reported in various types of cancer. mTOR is a multifunctional kinase that integrates growth factor and nutrient signals to regulate protein translation, nutrient uptake, autophagy, and mitochondrial function.
  • mTOR exists in two complexes, mTORC1 and mTORC2.
  • mTORC1 contains the raptor subunit and mTORC2 contains rictor.
  • These complexes are differentially regulated, and have distinct substrate specificities and rapamycin sensitivity.
  • mTORC1 phosphorylates S6 kinase (S6K) and 4EBP1, promoting increased translation and ribosome biogenesis to facilitate cell growth and cell cycle progression.
  • S6K also acts in a feedback pathway to attenuate PI3K/Akt activation.
  • mTORC2 is generally insensitive to rapamycin.
  • mTORC2 is though to modulate growth factor signaling by phosphorylating the C-terminal hydrophobic motif of some AGC kinases such as Akt. In many cellular contexts, mTORC2 is required for phosphorylation of the S473 site of Akt.
  • mTOR has drawn considerable attention due to its role in cell growth control and its involvement in human diseases.
  • mTor has been implicated in a wide range of disorders including but not limited to cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. It has been shown that mTOR modulates many fundamental biological processes including transcription, translation, autophagy, actin organization and ribosome biogenesis by integrating intracellular and extracellular signals, such as signals mediated by growth factors, nutrients, energy levels and cellular stress.
  • kinases particularly protein kinases such as mTor and Akt, as well as lipid kinases such as PI3Ks are prime targets for drug development.
  • the invention provides a method of treating a disorder in a subject in need thereof, comprising administering an mTorC1/mTorC2 inhibitor to said subject according to an intermittent regimen effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration at or above about 100 nM for a duration of time that is longer than that achieved by administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration of greater than about 100 nM for a duration longer than about 20 hours during a 7-day period of administration.
  • the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration of greater than about 100 nM for a duration of at least about 30 hours during a 7-day period of administration.
  • the invention further provides a method of treating a disorder in a subject in need thereof, comprising administering an mTorC1/mTorC2 inhibitor to said subject according to an intermittent regimen, such that the achieved Cmax is greater than that achieved by administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the intermittent regimen is effective to achieve a Cmax which is greater by about 10%, 20%, 30%, 40%, 50%, 100%, 200%, or 300% than the Cmax achieved by administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the intermittent regimen is effective to achieve a Cmax of greater than about 200, 250, 300, 350, 400, 450, 500, 550 or 600 nM.
  • the intermittent regimen is effective to achieve a Cmax of greater than about 300 nM.
  • the intermittent regimens of the invention may achieve similar or better pathway inhibition than administering an equivalent dose of the mTorC1/mTorC2 once daily.
  • the pathway inhibition is measured as percentage of decrease in phosphorylation of a protein chosen from p4EBP1, pS6, and pRAS40.
  • the intermittent regimens of the invention may also achieve similar or better therapeutic efficacy than administering an equivalent dose of the mTorC1/mTorC2 once daily. Further, the intermittent regimens of the invention may achieve at least the same level of tolerability as compared to administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily. In some embodiments, the level of tolerability is measured as the occurrence or lack of occurrence in the subject of a grade 3 or higher adverse event. For example, the adverse event is rash.
  • an intermittent regimen of the invention comprises at least one cycle in which the mTorC1/mTorC2 inhibitor is administered for at least 1 day, followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 1 day.
  • the mTorC1/mTorC2 inhibitor is administered for 2, 3, 4, 5, 6 or 7 consecutive days followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 1 day.
  • the regimen comprises at least one cycle in which the mTorC1/mTorC2 inhibitor is administered for 1 day followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for 6 consecutive days.
  • the regimen comprises at least one cycle in which the mTorC1/mTorC2 inhibitor is administered for 2, 3, 4, 5, 6 or 7 consecutive days followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 3, 4, or 5 consecutive days.
  • the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 3 consecutive days followed by an intermission of 4 consecutive days.
  • the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 5 consecutive days followed by an intermission of 2 consecutive days.
  • the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered at least 3 times on alternate days within the 7 days.
  • a dosage form for administration to a subject comprising an mTorC1/mTorC2 inhibitor, wherein the dosage form is formulated to provide a Cmax of greater than about 200 nM when administered to the subject.
  • the dosage form is capable of providing a plasma concentration of said mTorC1/mTorC2 inhibitor of greater than about 100 nM for a duration of time longer than about 20 hours during a 7-day period of administration.
  • the dosage form is capable of providing a plasma concentration of greater than 100 nM for a duration of time that is at least about 30 hours during a 7-day period of administration.
  • the dosage form comprises about 45, 50, 55, 60, 70, 75 mg or less of the mTorC1/mTorC2 inhibitor.
  • the invention also provides a method of treating a disorder in a subject in need thereof, comprising administering a dosage form of the invention.
  • kits comprising a dosage form as described and additionally comprising instructions for administration to a subject in need thereof.
  • the instructions provide for at least one 7-day cycle of administration to the subject for 2, 3, 4, or 5 consecutive days followed by an intermission of 5, 4, 3, or 2 days, respectively.
  • the instructions provide for administration of the mTorC1/mTorC2 inhibitor to the subject for 3 consecutive days followed by an intermission of 4 consecutive days.
  • the invention further provides a pharmaceutical regimen for the treatment of a disorder, the regimen comprising an mTorC1/mTorC2 inhibitor, wherein the regimen provides an area under the curve that is similar to that obtained by administering the mTorC1/mTorC2 inhibitor once daily, and wherein the regimen results in higher therapeutic efficacy as compared to administering said inhibitor once daily.
  • the disorders to be treated include, but are not limited to, a neoplastic condition, autoimmune disease, inflammatory disease, fibrotic disease or kidney disease.
  • the disorder is a neoplastic condition such as cancer.
  • the mTorC1/mTorC2 inhibitor may be administered parenterally, orally, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally. In some embodiments, the mTorC1/mTorC2 inhibitor is administered orally.
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay, and that the mTorC1/mTorC2 inhibitor is substantially inactive against one or more types I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor is a compound of Formula I:
  • X 1 is N or C-E 1
  • X 2 is N or C
  • X 3 is N or C
  • X 4 is C—R 9 or N
  • X 5 is N or C-E 1
  • X 6 is C or N
  • X 7 is C or N; and wherein no more than two nitrogen ring atoms are adjacent;
  • R 1 is H, -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl, —C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylhetaryl, -L-C 1-10 alkylheterocylyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloal
  • the mTorC1/mTorC2 inhibitor has the Formula:
  • R 2 is H. In other embodiments, R 1 is isopropyl. In other embodiments, R 1 is
  • R 1 is
  • R 1 is
  • E 2 is —H; X 1 is CH; X 2 is N; W 2 is —NH; R 2 is H; k is 1; and R 1 is isopropyl or
  • FIG. 1 shows the Cmax observed upon administration of compound A at various dose levels.
  • FIG. 2 shows the area under the curve (AUC) upon administration of compound A at various dose levels.
  • FIG. 3 shows plasma concentration-time profiles for compound A administered at various dose levels.
  • FIG. 4 shows modeled pharmacokinetic properties of compound A.
  • FIG. 5 shows mTor C pathway inhibition in peripheral blood mono-nucleocytes by an intermittent dosing regimen using compound A.
  • FIG. 6 shows mTor C pathway inhibition (p4EBP1) in skin biopsies by an intermittent dosing regimen using compound A.
  • FIG. 7 shows mTor C pathway inhibition (pS6) in skin biopsies by an intermittent dosing regimen using compound A.
  • FIG. 8 shows mTor C pathway inhibition (pPRAS40) in skin biopsies by an intermittent dosing regimen using compound A.
  • the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.
  • Treatment “Treatment”, “treating”, “palliating” and “ameliorating”, as used herein, are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
  • the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • the term “neoplastic condition” refers to the presence of cells possessing abnormal growth characteristics, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, perturbed oncogenic signaling, and certain characteristic morphological features. This includes but is not limited to the growth of: (1) benign or malignant cells (e.g., tumor cells) that correlates with overexpression of a tyrosine or serine/threonine kinase; (2) benign or malignant cells (e.g., tumor cells) that correlates with abnormally high level of tyrosine or serine/threonine kinase activity.
  • benign or malignant cells e.g., tumor cells
  • benign or malignant cells e.g., tumor cells
  • Exemplary tyrosine kinases implicated in a neoplastic condition include but are not limited to receptor tyrosine kinases such as epidermal growth factor receptors (EGF receptor), platelet derived growth factor (PDGF) receptors, and cyotsolic tyrosine kinases such as src and abl kinase.
  • receptor tyrosine kinases such as epidermal growth factor receptors (EGF receptor), platelet derived growth factor (PDGF) receptors
  • cyotsolic tyrosine kinases such as src and abl kinase.
  • Non-limiting serine/threonine kinases implicated in neoplastic condition include but are not limited to raf and mek.
  • the term “effective amount” or “therapeutically effective amount” refers to that amount of an inhibitor described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below.
  • the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • the term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein.
  • the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
  • a “sub-therapeutic amount” of an agent or therapy is an amount less than the effective amount for that agent or therapy, but when combined with an effective or sub-therapeutic amount of another agent or therapy can produce a result desired by the physician, due to, for example, synergy in the resulting efficacious effects, or reduced side effects.
  • a “synergistically effective” therapeutic amount or “synergistically effective” amount of an agent or therapy is an amount which, when combined with an effective or sub-therapeutic amount of another agent or therapy, produces a greater effect than when either of the two agents are used alone.
  • a syngergistically effective therapeutic amount of an agent or therapy produces a greater effect when used in combination than the additive effects of each of the two agents or therapies when used alone.
  • the term “greater effect” encompasses not only a reduction in symptoms of the disorder to be treated, but also an improved side effect profile, improved tolerability, improved patient compliance, improved efficacy, or any other improved clinical outcome.
  • agent refers to a biological, pharmaceutical, or chemical compound or other moiety.
  • Non-limiting examples include simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound.
  • Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures.
  • various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.
  • agonist refers to a compound having the ability to initiate or enhance a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the term “agonist” is defined in the context of the biological role of the target polypeptide. While preferred agonists herein specifically interact with (e.g., bind to) the target, compounds that initiate or enhance a biological activity of the target polypeptide by interacting with other members of the signal transduction pathway of which the target polypeptide is a member are also specifically included within this definition.
  • antagonists are used interchangeably, and they refer to a compound having the ability to inhibit a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the terms “antagonist” and “inhibitors” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g., bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition.
  • a preferred biological activity inhibited by an antagonist is associated with the development, growth, or spread of a tumor, or an undesired immune response as manifested in autoimmune disease.
  • mTorC1/C2 inhibitor refers to an mTOR inhibitor that interacts with and reduces the kinase activity of both mTORC1 and mTORC2 complexes.
  • an “anti-neoplastic”, “anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition.
  • One class of anti-cancer agents comprises chemotherapeutic agents.
  • “Chemotherapy” means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository.
  • antiangiogenic refers to the ability to inhibit or impair the formation of blood vessels, including but not limited to inhibiting endothelial cell proliferation, endothelial cell migration, and capillary tube formation.
  • cell proliferation refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.
  • co-administration encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time.
  • Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
  • Co-administered agents may be in the same formulation.
  • Co-administered agents may also be in different formulations.
  • a “therapeutic effect,” as used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above.
  • a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
  • pharmaceutically acceptable salt refers to salts derived from a variety of organic and inorganic counter ions well known in the art.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
  • “Pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Signal transduction is a process during which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response.
  • a modulator of a signal transduction pathway refers to a compound that modulates the activity of one or more cellular proteins mapped to the same specific signal transduction pathway.
  • a modulator may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.
  • selective inhibition or “selectively inhibit” as applied to a biologically active agent refers to the agent's ability to selectively reduce the target signaling activity as compared to off-target signaling activity, via direct or interact interaction with the target.
  • Subject refers to an animal, such as a mammal, for example a human.
  • the methods described herein can be useful in both human therapeutics, pre-clinical, and veterinary applications.
  • the subject is a mammal, and in some embodiments, the subject is human.
  • in vivo refers to an event that takes place in a subject's body.
  • in vitro refers to an event that takes places outside of a subject's body.
  • an in vitro assay encompasses any assay run outside of a subject assay.
  • in vitro assays encompass cell-based assays in which cells alive or dead are employed.
  • In vitro assays also encompass a cell-free assay in which no intact cells are employed.
  • connection of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any linking moieties, and ends with the linking moiety.
  • heteroarylthio C 1-4 alkyl has a heteroaryl group connected through a thio sulfur to a C 1-4 alkyl radical that connects to the chemical species bearing the substituent.
  • the terminal group is a C 3-8 cycloalkyl group attached to a linking C 1-10 alkyl moiety which is attached to an element L, which is itself connected to the chemical species bearing the substituent.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C 1 -C 10 alkyl). Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, it is a C 1 -C 4 alkyl group.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl isobutyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, decyl, and the like.
  • the alkyl is attached to the rest of the molecule by a single bond, for example, methyl (Me), ethyl (Et), n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
  • an alkyl group is optionally substituted by one or more of substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)OR a , —N(R a )C(O)R
  • halo or halogen refers to fluoro, chloro, bromo, or iodo.
  • haloalkyl refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, and the like.
  • “Acyl” refers to the groups (alkyl)-C(O)—, (aryl)-C(O)—, (heteroaryl)-C(O)—, (heteroalkyl)-C(O)—, and (heterocycloalkyl)-C(O)—, wherein the group is attached to the parent structure through the carbonyl functionality.
  • it is a C 1 -C 10 acyl radical which refers to the total number of chain or ring atoms of the alkyl, aryl, heteroaryl or heterocycloalkyl portion of the acyloxy group plus the carbonyl carbon of acyl, i.e three other ring or chain atoms plus carbonyl.
  • R radical is heteroaryl or heterocycloalkyl
  • the hetero ring or chain atoms contribute to the total number of chain or ring atoms.
  • the “R” of an acyloxy group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —C(O)
  • Cycloalkyl refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and may be saturated, or partially unsaturated. Cycloalkyl groups include groups having from 3 to 10 ring atoms (i.e., C 2 -C 10 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 10 carbon atoms” means that the cycloalkyl group may consist of 3 carbon atoms, etc., up to and including 10 carbon atoms. In some embodiments, it is a C 3 -C 8 cycloalkyl radical.
  • cycloalkyl groups include, but are not limited to the following moieties: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloseptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl, and the like.
  • a cycloalkyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)OR a , —N(R a )C(
  • C 1-10 alkyl-C 3-8 cycloalkyl is used to describe an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking cycloalkyl group which contains 3 to 8 carbons, such as for example, 2-methyl cyclopropyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • bicycloalkyl refers to a structure consisting of two cycloalkyl moieties, unsubstituted or substituted, that have two or more atoms in common If the cycloalkyl moieties have exactly two atoms in common they are said to be “fused”. Examples include, but are not limited to, bicyclo[3.1.0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl moieties have more than two atoms in common they are said to be “bridged”. Examples include, but are not limited to, bicyclo[3.2.1]heptyl (“norbornyl”), bicyclo[2.2.2]octyl, and the like.
  • heteroatom or “ring heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
  • Heteroalkyl “heteroalkenyl” and “heteroalkynyl” include optionally substituted alkyl, alkenyl and alkynyl radicals and which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof
  • a numerical range may be given, e.g., C 1 -C 4 heteroalkyl which refers to the chain length in total, which in this example is 4 atoms long.
  • a —CH 2 OCH 2 CH 3 radical is referred to as a “C 4 ” heteroalkyl, which includes the heteroatom center in the atom chain length description.
  • a heteroalkyl group may be substituted with one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)OR a , —N(R a )C(O)R a , —N(R a )C(O)OR
  • heteroalkylaryl refers to a heteroalkyl group as defined above which is attached to an aryl group, and may be attached at a terminal point or through a branched portion of the heteroalkyl, for example, an benzyloxymethyl moiety. Either portion of the moiety is unsubstituted or substituted.
  • heteroalkylheteroaryl refers likewise to a heteroalkyl group which is attached to a heteroaryl moiety, for example, an ethoxymethylpyridyl group. Either portion of the moiety is unsubstituted or substituted.
  • heteroalkyl-heterocyclyl refers to a heteroalkyl group as defined above, which is attached to a heterocyclic group, for example, 4(3-aminopropyl)-N-piperazinyl. Either portion of the moiety is unsubstituted or substituted.
  • heteroalkyl-C 3-8 cycloalkyl refers to a heteroalkyl group as defined above, which is attached to a cyclic alkyl containing 3 to 8 carbons, for example, 1-aminobutyl-4-cyclohexyl. Either portion of the moiety is unsubstituted or substituted.
  • heterocycloalkyl refers to a bicycloalkyl structure, which is unsubstituted or substituted, in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.
  • heterospiroalkyl refers to a spiroalkyl structure, which is unsubstituted or substituted, in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.
  • alkene refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond
  • an “alkyne” moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond.
  • the alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.
  • Alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e., C 2 -C 10 alkenyl). Whenever it appears herein, a numerical range such as “2 to 10” refers to each integer in the given range; e.g., “2 to 10 carbon atoms” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms.
  • an alkenyl comprises two to five carbon atoms (e.g., C 2 -C 5 alkenyl).
  • the alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.
  • an alkenyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)R a ,
  • C 2-10 alkenyl-heteroalkyl refers to a group having an alkenyl moiety, containing 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroalkyl group, such as, for example, allyloxy, and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkynyl-heteroalkyl refers to a group having an alkynyl moiety, which is unsubstituted or substituted, containing 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroalkyl group, such as, for example, 4-but-1-ynoxy, and the like. Either portion of the moiety is unsubstituted or substituted.
  • haloalkenyl refers to an alkenyl group substituted with one or more halo groups.
  • cycloalkenyl refers to a cyclic aliphatic 3 to 8 membered ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1,4-cyclohexadienyl, and the like.
  • Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to ten carbon atoms (i.e., C 2 -C 10 alkynyl). Whenever it appears herein, a numerical range such as “2 to 10” refers to each integer in the given range; e.g., “2 to 10 carbon atoms” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms.
  • an alkynyl has two to five carbon atoms (e.g., C 2 -C 5 alkynyl).
  • the alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)R a , —N(R a )C(O)OR
  • C 2-10 alkynyl-C 3-8 cycloalkyl refers to a group containing an alkynyl group, containing 2 to 10 carbons and branched or straight chain, which is attached to a linking cycloalkyl group containing 3 to 8 carbons, such as, for example 3-prop-3-ynyl-cyclopent-lyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • haloalkynyl refers to an alkynyl group substituted with one or more independent halo groups.
  • Amino or “amine” refers to a —N(R a ) 2 radical group, where each R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, unless stated otherwise specifically in the specification.
  • R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, unless stated otherwise specifically in the specification.
  • R a is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl
  • —N(R a ) 2 is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • an amino group is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a ) 2 , —N(
  • “Amide” or “amido” refers to a chemical moiety with formula —C(O)N(R) 2 or —NHC(O)R, where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), each of which moiety may itself be optionally substituted. In some embodiments it is a C 1 -C 4 amido or amide radical, which includes the amide carbonyl in the total number of carbons in the radical.
  • the R 2′ of —N(R) 2 of the amide may optionally be taken together with the nitrogen to which it is attached to form a 4-, 5-, 6-, or 7-membered ring.
  • an amido group is optionally substituted independently by one or more of the substituents as described herein for alkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl.
  • An amide may be an amino acid or a peptide molecule attached to a compound of Formula (I), thereby forming a prodrug. Any amine, hydroxy, or carboxyl side chain on the compounds described herein can be amidified.
  • “Aromatic” or “aryl” refers to an aromatic radical with six to ten ring atoms (e.g., C 6 -C 10 aromatic or C 6 -C 10 aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl).
  • Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
  • Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
  • a numerical range such as “6 to 10” refers to each integer in the given range; e.g., “6 to 10 ring atoms” means that the aryl group may consist of 6 ring atoms, 7 ring atoms, etc., up to and including 10 ring atoms.
  • an aryl moiety is optionally substituted by one or more substituents which are independently: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —OC(O)N(R a ) 2 , —C(O)N(R a ) 2 , —N(R a )
  • Heteroaryl or, alternatively, “heteroaromatic” refers to a 5- to 18-membered aromatic radical (e.g., C 5 -C 13 heteroaryl) that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur, and which may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system.
  • a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group may consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • An N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
  • the polycyclic heteroaryl group may be fused or non-fused.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized.
  • heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzof
  • a heteraryl moiety is optionally substituted by one or more substituents which are independently: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)OR a , —N(R a )C(O)R a , —N(R a )S(
  • aryl-alkyl arylalkyl
  • arylalkyl arylalkyl
  • aralkyl a group wherein the alkyl chain can be branched or straight chain forming a linking portion with the terminal aryl, as defined above, of the aryl-alkyl moiety.
  • aryl-alkyl groups include, but are not limited to, optionally substituted benzyl, phenethyl, phenpropyl and phenbutyl such as 4-chlorobenzyl, 2,4-dibromobenzyl, 2-methylbenzyl, 2-(3-fluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(4-(trifluoromethyl)phenyl)ethyl, 2-(2-methoxyphenyl)ethyl, 2-(3-nitrophenyl)ethyl, 2-(2,4-dichlorophenyl)ethyl, 2-(3,5-dimethoxyphenyl)ethyl, 3-phenylpropyl, 3-(3-chlorophenyl)propyl, 3-(2-methylphenyl)propyl, 3-(4-methoxyphenyl)propyl, 3-(4-(trifluoromethyl)phenyl)propyl
  • C 1-10 alkylaryl refers to an alkyl group, as defined above, containing 1 to 10 carbon atoms, branched or unbranched, wherein the aryl group replaces one hydrogen on the alkyl group, for example, 3-phenylpropyl. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkyl monocycloaryl refers to a group containing a terminal alkyl group, branched or straight chain and containing 2 to 10 atoms attached to a linking aryl group which has only one ring, such as for example, 2-phenyl ethyl. Either portion of the moiety is unsubstituted or substituted.
  • C 1-10 alkyl bicycloaryl refers to a group containing a terminal alkyl group, branched or straight chain and containing 2 to 10 atoms attached to a linking aryl group which is bicyclic, such as for example, 2-(1-naphthyl)-ethyl. Either portion of the moiety is unsubstituted or substituted.
  • aryl-cycloalkyl and “arylcycloalkyl” are used to describe a group wherein the terminal aryl group is attached to a cycloalkyl group, for example phenylcyclopentyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-C 3-8 cycloalkyl and “heteroaryl-C 3-8 cycloalkyl” are used to describe a group wherein the terminal heteroaryl group is attached to a cycloalkyl group, which contains 3 to 8 carbons, for example pyrid-2-yl-cyclopentyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-heteroalkyl refers to a group wherein the terminal heteroaryl group is attached to a linking heteroalkyl group, such as for example, pyrid-2-yl methylenoxy, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-alkenyl arylalkenyl
  • arylalkenyl arylalkenyl
  • aralkenyl are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a linking portion of the aralkenyl moiety with the terminal aryl portion, as defined above, for example styryl (2-phenylvinyl), phenpropenyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-C 2-10 alkenyl means an arylalkenyl as described above wherein the alkenyl moiety contains 2 to 10 carbon atoms such as for example, styryl (2-phenylvinyl), and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkenyl-aryl is used to describe a group wherein the terminal alkenyl group, which contains 2 to 10 carbon atoms and can be branched or straight chain, is attached to the aryl moiety which forms the linking portion of the alkenyl-aryl moiety, such as for example, 3-propenyl-naphth-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-alkynyl arylalkynyl
  • arylalkynyl arylalkynyl
  • aralkynyl are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the aryl-alkynyl moiety with the terminal aryl portion, as defined above, for example 3-phenyl-1-propynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-C 2-10 alkynyl means an arylalkynyl as described above wherein the alkynyl moiety contains two to ten carbons, such as, for example 3-phenyl-1-propynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkynyl-aryl means a group containing an alkynyl moiety attached to an aryl linking group, both as defined above, wherein the alkynyl moiety contains two to ten carbons, such as, for example 3-propynyl-naphth-1-yl. Either portion of the moiety is unsubstituted or substituted.
  • aryl-oxy aryloxy
  • aryloxy and “aroxy” are used to describe a terminal aryl group attached to a linking oxygen atom.
  • Typical aryl-oxy groups include phenoxy, 3,4-dichlorophenoxy, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-oxyalkyl refers to a group wherein an alkyl group is substituted with a terminal aryl-oxy group, for example pentafluorophenoxymethyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 1-10 alkoxy-C 1-10 alkyl refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example methoxypropyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 1-10 alkoxy-C 2-10 alkenyl refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkenyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example 3-methoxybut-2-en-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 1-10 alkoxy-C 2-10 alkynyl refers to a group wherein an alkoxy group, containing 1 to 10 carbon atoms and an oxygen atom within the branching or straight chain, is attached to a linking alkynyl group, branched or straight chain which contains 1 to 10 carbon atoms, such as, for example 3-methoxybut-2-in-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocycloalkenyl refers to a cycloalkenyl structure, which is unsubstituted or substituted in which at least one carbon atom is replaced with a heteroatom selected from oxygen, nitrogen, and sulfur.
  • heteroaryl-oxy refers to a terminal heteroaryl group, which is unsubstituted or substituted, attached to a linking oxygen atom.
  • Typical heteroaryl-oxy groups include 4,6-dimethoxypyrimidin-2-yloxy and the like.
  • heteroarylalkyl refers to a group wherein the alkyl chain can be branched or straight chain forming a linking portion of the heteroaralkyl moiety with the terminal heteroaryl portion, as defined above, for example 3-furylmethyl, thenyl, furfuryl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-C 1-10 alkyl is used to describe a heteroaryl alkyl group as described above where the alkyl group contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.
  • C 1-10 alkyl-heteroaryl is used to describe a alkyl attached to a hetary group as described above where the alkyl group contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.
  • heteroarylalkenyl refers to a heteroarylalkenyl group wherein the alkenyl chain can be branched or straight chain forming a linking portion of the heteroaralkenyl moiety with the terminal heteroaryl portion, as defined above, for example 3-(4-pyridyl)-1-propenyl. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-C 2-10 alkenyl group is used to describe a group as described above wherein the alkenyl group contains 2 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkenyl-heteroaryl is used to describe a group containing an alkenyl group, which is branched or straight chain and contains 2 to 10 carbon atoms, and is attached to a linking heteroaryl group, such as, for example 2-styryl-4-pyridyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroarylalkynyl refers to a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the heteroaralkynyl moiety with the heteroaryl portion, as defined above, for example 4-(2-thienyl)-1-butynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-C 2-10 alkynyl is used to describe a heteroarylalkynyl group as described above wherein the alkynyl group contains 2 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkynyl-heteroaryl is used to describe a group containing an alkynyl group which contains 2 to 10 carbon atoms and is branched or straight chain, which is attached to a linking heteroaryl group such as, for example, 4(but-1-ynyl) thien-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclyl refers to a four-, five-, six-, or seven-membered ring containing one, two, three or four heteroaroms independently selected from nitrogen, oxygen and sulfur.
  • the four-membered ring has zero double bonds
  • the five-membered ring has zero to two double bonds
  • the six- and seven-membered rings have zero to three double bonds.
  • heterocyclyl also includes bicyclic groups in which the heterocyclyl ring is fused to another monocyclic heterocyclyl group, or a four- to se-membered aromatic or nonaromatic carbocyclic ring.
  • the heterocyclyl group can be attached to the parent molecular moiety through any carbon atom or nitrogen atom in the group.
  • Heterocycloalkyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Whenever it appears herein, a numerical range such as “3 to 18” refers to each integer in the given range; e.g., “3 to 18 ring atoms” means that the heterocycloalkyl group may consist of 3 ring atoms, 4 ring atoms, etc., up to and including 18 ring atoms. In some embodiments, it is a C 5 -C 10 heterocycloalkyl. In some embodiments, it is a C 4 -C 10 heterocycloalkyl.
  • the heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
  • the heteroatoms in the heterocycloalkyl radical may be optionally oxidized.
  • One or more nitrogen atoms, if present, are optionally quaternized.
  • the heterocycloalkyl radical is partially or fully saturated.
  • the heterocycloalkyl may be attached to the rest of the molecule through any atom of the ring(s).
  • heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-o-
  • a heterocycloalkyl moiety is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, —OR a , SR a , —OC(O)—R a , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR a , —N(R a )C(O)OR a , —N(R a )C(O)R a , —N(R a )S(
  • Heterocycloalkyl also includes bicyclic ring systems wherein one non-aromatic ring, usually with 3 to 7 ring atoms, contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms; and the other ring, usually with 3 to 7 ring atoms, optionally contains 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen and is not aromatic.
  • heterocyclylalkyl refers to the divalent derivative of heterocycloalkyl.
  • C 1-10 alkyl-heterocycyl refers to a group as defined above where the alkyl moiety contains 1 to 10 carbon atoms. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclic group refers to a group containing a terminal heterocyclic group attached to a linking alkyl group which contains 1 to 10 carbons and is branched or straight chain, such as, for example, 4-morpholinyl ethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclylalkenyl refers to the divalent derivative of heterocyclylalkenyl. Either portion of the moiety is unsubstituted or substituted.
  • heterocycyl-C 2-10 alkenyl refers to a group as defined above where the alkenyl group contains 2 to 10 carbon atoms and is branched or straight chain, such as, for example, 4-(N-piperazinyl)-but-2-en-1-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclylalkynyl refers to a group wherein the alkynyl chain can be branched or straight chain forming a linking portion of the heterocyclylalkynyl moiety with the terminal heterocyclyl portion, as defined above, for example 2-pyrrolidinyl-1-butynyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocycyl-C 2-10 alkynyl refers to a group as defined above where the alkynyl group contains 2 to 10 carbon atoms and is branched or straight chain, such as, for example, 4-(N-piperazinyl)-but-2-yn-1-yl, and the like.
  • aryl-heterocycyl refers to a group containing a terminal aryl group attached to a linking heterocyclic group, such as for example, N4-(4-phenyl)-piperazinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heteroaryl-heterocycyl refers to a group containing a terminal heteroaryl group attached to a linking heterocyclic group, such as for example, N4-(4-pyridyl)-piperazinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • carboxylalkyl refers to a terminal carboxyl (—COOH) group attached to branched or straight chain alkyl groups as defined above.
  • carboxylalkenyl refers to a terminal carboxyl (—COOH) group attached to branched or straight chain alkenyl groups as defined above.
  • carboxylalkynyl refers to a terminal carboxyl (—COOH) group attached to branched or straight chain alkynyl groups as defined above.
  • carboxylcycloalkyl refers to a terminal carboxyl (—COOH) group attached to a cyclic aliphatic ring structure as defined above.
  • carboxylcycloalkenyl refers to a terminal carboxyl (—COOH) group attached to a cyclic aliphatic ring structure having ethylenic bonds as defined above.
  • cycloalkylalkyl and “cycloalkyl-alkyl” refer to a terminal cycloalkyl group as defined above attached to an alkyl group, for example cyclopropylmethyl, cyclohexylethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • cycloalkylalkenyl and “cycloalkyl-alkenyl” refer to a terminal cycloalkyl group as defined above attached to an alkenyl group, for example cyclohexylvinyl, cycloheptylallyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • cycloalkylalkynyl and “cycloalkyl-alkynyl” refer to a terminal cycloalkyl group as defined above attached to an alkynyl group, for example cyclopropylpropargyl, 4-cyclopentyl-2-butynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • cycloalkenylalkyl and “cycloalkenyl-alkyl” refer to a terminal cycloalkenyl group as defined above attached to an alkyl group, for example 2-(cyclopenten-1-yl)ethyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • cycloalkenylalkenyl and “cycloalkenyl-alkenyl” refer to terminal a cycloalkenyl group as defined above attached to an alkenyl group, for example 1-(cyclohexen-3-yl)allyl and the like.
  • cycloalkenylalkynyl and “cycloalkenyl-alkynyl” refer to terminal a cycloalkenyl group as defined above attached to an alkynyl group, for example 1-(cyclohexen-3-yl)propargyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • alkoxy refers to the group —O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C 1 -C 4 alkyl, is an alkyl group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms.
  • haloalkoxy refers to an alkoxy group substituted with one or more halo groups, for example chloromethoxy, trifluoromethoxy, difluoromethoxy, perfluoroisobutoxy, and the like.
  • alkoxyalkoxyalkyl refers to an alkyl group substituted with an alkoxy moiety which is in turn is substituted with a second alkoxy moiety, for example methoxymethoxymethyl, isopropoxymethoxyethyl, and the like. This moiety is substituted with further substituents or not substituted with other substituents.
  • alkylthio includes both branched and straight chain alkyl groups attached to a linking sulfur atom, for example methylthio and the like.
  • alkoxyalkyl refers to an alkyl group substituted with an alkoxy group, for example isopropoxymethyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • alkoxyalkenyl refers to an alkenyl group substituted with an alkoxy group, for example 3-methoxyallyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • alkoxyalkynyl refers to an alkynyl group substituted with an alkoxy group, for example 3-methoxypropargyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkenylC 3-8 cycloalkyl refers to an alkenyl group as defined above substituted with a three to eight membered cycloalkyl group, for example, 4-(cyclopropyl)-2-butenyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • C 2-10 alkynylC 3-8 cycloalkyl refers to an alkynyl group as defined above substituted with a three to eight membered cycloalkyl group, for example, 4-(cyclopropyl)-2-butynyl and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclyl-C 1-10 alkyl refers to a heterocyclic group as defined above substituted with an alkyl group as defined above having 1 to 10 carbons, for example, 4-(N-methyl)-piperazinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclyl-C 2-10 alkenyl refers to a heterocyclic group as defined above, substituted with an alkenyl group as defined above, having 2 to 10 carbons, for example, 4-(N-allyl) piperazinyl, and the like. Moieties wherein the heterocyclic group is substituted on a carbon atom with an alkenyl group are also included. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclyl-C 2-10 alkynyl refers to a heterocyclic group as defined above, substituted with an alkynyl group as defined above, having 2 to 10 carbons, for example, 4-(N-propargyl) piperazinyl, and the like. Moieties wherein the heterocyclic group is substituted on a carbon atom with an alkenyl group are also included. Either portion of the moiety is unsubstituted or substituted.
  • oxo refers to an oxygen that is double bonded to a carbon atom.
  • an “oxo” requires a second bond from the atom to which the oxo is attached. Accordingly, it is understood that oxo cannot be subststituted onto an aryl or heteroaryl ring, unless it forms part of the aromatic system as a tautomer.
  • oligomer refers to a low-molecular weight polymer, whose number average molecular weight is typically less than about 5000 g/mol, and whose degree of polymerization (average number of monomer units per chain) is greater than one and typically equal to or less than about 50.
  • “Sulfonamidyl” or “sulfonamido” refers to a S( ⁇ O) 2 —NR′R′ radical, where each R′ is selected independently from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon).
  • the R′ groups in NR′R′ of the S( ⁇ O) 2 —NR′R′ radical may be taken together with the nitrogen to which it is attached to form a 4-, 5-, 6-, or 7-membered ring.
  • a sulfonamido group is optionally substituted by one or more of the substituents described for alkyl, cycloalkyl, aryl, heteroaryl respectively.
  • Compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Compounds may be shown without a definitive stereochemistry at certain positions.
  • the present invention includes all stereoisomers of the disclosed compounds and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • the present invention includes all manner of rotamers and conformationally restricted states of an inhibitor of the invention.
  • Substituents for alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl monovalent and divalent derivative radicals can be one or more of a variety of groups selected from, but not limited to: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —OR a , ⁇ O, ⁇ NR′, ⁇ N—OR a , —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R
  • R′, R′′, R′′′ and R′′′ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R′, R′′, R′′′ and R′′′ groups when more than one of these groups is present.
  • R′ and R′′ or R′′ and R′′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
  • —NR′R′′ is meant to include, but not be limited to, 1-pyrrolidinyl, 4 piperazinyl, and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., —CF 3 and —CH 2 CF 3
  • acyl e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like.
  • exemplary substituents for aryl and heteroaryl groups are varied and are selected from, for example: halogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —OR a , —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —C(O)NR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O)OR′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′, —NR—C(
  • 0-2 in the context of —S(O) (0-2) — are integers of 0, 1, and 2.
  • Two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′) q —U—, wherein T and U are independently NR—, —O—, —CRR′— or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r —B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′— or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′) s —X′—(C′′R′′′) d —, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
  • the substituents R, R′, R′′ and R′′′ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C— or 14 C-enriched carbon are within the scope of this invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
  • the invention provides an intermittent treatment regimen in which an mTorC1/mTorC2 inhibitor is administered to a subject and where the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration at or above about 100 nM for a duration of time that is longer than that achieved by administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the term “equivalent dose” refers to a single or multiple dose administered to a subject over a period of time, including a day, several days, a week, a month or longer. In some embodiments, equivalence is evaluated during the length of a treatment cycle, e.g. a week.
  • equivalent dose is not limited to identical amounts of a compound administered of a specified period of time, but also refers to dose amounts which result in a similar level of tolerability.
  • a regimen of the invention in which an mTorC1/mTorC2 inhibitor is administered intermittently at a weekly cumulative dose of 50 mg with a regimen in which the mTorC1/mTorC2 inhibitor is administered daily, it may only possible to achieve a weekly cumulative dose of less than 50 mg (e.g. about 40-45 mg) using daily administration due to dose-limiting toxicity and/or limited tolerability.
  • administration of the weekly cumulative 50 mg dose in the intermittent regimen is “equivalent” to the about 40-45 mg weekly cumulative dose administered daily.
  • the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration of greater than about 80, 90, 100, 100, 120, 130, 140, 150, or 160 nM for a duration longer than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 hours during a 7-day period of administration.
  • the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration of greater than about 100 nM for a duration longer than about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 hours during a 7-day period of administration.
  • the intermittent regimen is effective to achieve an mTorC1/mTorC2 inhibitor plasma concentration of greater than about 100 nM for a duration longer than about 20 or about 30 hours during a 7-day period of administration.
  • the invention also provides a treatment regimen which is effective to achieve a Cmax which is greater by about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, or 300% than the Cmax achieved by administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the Cmax achieved is greater than about 100, 200, 250, 300, 350, 400, 450, 500, 550 or 600 nM.
  • the Cmax achieved is greater than about 200, 250, 300, 350, 400, 450, 500, 550 or 600 nM.
  • the Cmax is greater than 200 nM.
  • the Cmax is greater than 300 nM.
  • the Cmax achieved is between 200 and 600 nM.
  • the Cmax achieved is between 200 and 500 nM.
  • the Cmax achieved is between 200 and 500 nM.
  • an intermittent treatment regimen of the invention achieves similar or better pathway inhibition than administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • Pathway inhibition may be measured, for example, as a percentage decrease in phosphorylation of a protein chosen from p4EBP1, pS6, and pRAS40.
  • pathway inhibition is measured as a 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater decrease in phosphorylation of p4EBP1.
  • phosphorylation of p4EBP1 is reduced by at least 60%.
  • pathway inhibition is measured as a 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater decrease in phosphorylation of pS6.
  • phosphorylation of pS6 is reduced by at least 60%.
  • pathway inhibition is measured as a 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater decrease in phosphorylation of pRAS40.
  • phosphorylation of pRAS40 is reduced by at least 60%.
  • pathway inhibition is measured as a 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater decrease in phosphorylation of p4EBP1, pS6, and pRAS40.
  • phosphorylation of p4EBP1, pS6, and pRAS40 is reduced by at least 60%.
  • pathway inhibition is measured in peripheral blood cells.
  • pathway inhibition is measured in a biopsy, for example a skin biopsy.
  • an intermittent treatment regimen of the invention achieves similar or better level of tolerability as compared to administering an equivalent dose of the mTorC1/mTorC2 inhibitor once daily.
  • the level of tolerability may be measured, for example, as the occurrence or lack of occurrence of a grade 3 or higher adverse event.
  • the adverse event is rash, hyperglycaemia, lymphopenia, diarrhoea, gamma-glutamyltransferase increase, hypokalaemia, hyponatraemia, pruritus, thrombocytopenia, upper abdominal pain, anaemia, aspartate aminotransferase increase, asthenia, catheter related infection, cellulitis, disease progression, enterocutaneous fistula, gastroenteritis, acute pancreatitis, pleural effusion, macular rash, somnolence, or urinary tract infection.
  • the adverse event is rash.
  • a given dosing schedule comprises one or more administrations of an mTorC1/mTorC2 inhibitor, wherein at least one administration of an mTorC1/mTorC2 inhibitor, such as described herein, may be repeated or cycled on a daily, weekly, biweekly, monthly, bimonthly, annually, semi-annually, or any other period.
  • a repeated dosing schedule or cycle may be repeated for a fixed period of time determined at the start of the schedule; may be terminated, extended, or otherwise adjusted based on a measure of therapeutic effect, such as a level of reduction in the presence of detectable disease tissue (e.g. a reduction of at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%); or may be terminated, extended, or otherwise adjusted for any other reason as determined by a medical professional.
  • the intermittent regimen comprises at least one cycle in which the mTorC1/mTorC2 inhibitor is administered for at least 1 day, followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 1 day.
  • the mTorC1/mTorC2 inhibitor is administered for 2, 3, 4, 5, 6 or 7 consecutive days followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 1 day, for example not administered for at least 1, 2, 3, 4, 5, 6, or 7 days.
  • the mTorC1/mTorC2 inhibitor is administered for 7, 8, 9, 10, 11, 12, 13, or 14 consecutive days, followed by an intermission where the mTorC1/mTorC2 inhibitor is not administered for at least 2, 3, 4, 5, 6, or 7 days.
  • the mTorC1/mTorC2 inhibitor is administered for 2, 3, 4, 5, 6 or 7 consecutive days followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 3, 4, or 5 consecutive days.
  • the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 3 consecutive days followed by an intermission of 4 consecutive days.
  • the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 4 consecutive days followed by an intermission of 3 consecutive days. In yet other embodiments, the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 5 consecutive days followed by an intermission of 2 consecutive days. In yet other embodiments, the regimen comprises at least one 7-day cycle in which the mTorC1/mTorC2 inhibitor is administered for 6 consecutive days followed by an intermission of 1 day.
  • an mTorC1/mTorC2 inhibitor, and/or any additional therapeutic compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day or per week. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In some embodiments, cycles of administering an mTorC1/mTorC2 inhibitor followed by periods of rest (intermission) are repeated for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, repetition of a dosing cycle comprising administration of an mTorC1/mTorC2 inhibitor followed by rest are continued as long as necessary.
  • an mTorC1/mTorC2 inhibitor of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, an mTorC1/mTorC2 inhibitor of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, an mTorC1/mTorC2 inhibitor of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
  • the amount of the mTorC1/mTorC2 inhibitor administered herein may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • a dosage form of the invention refers to the physical formulation of a drug for administration to the patient.
  • the dosage form can be a single capsule, tablet, or pill, or alternatively can be comprised of multiple capsules, tablets or pills.
  • a dosage form may be administered to a subject once or multiple times per day. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell or tissue being treated, and the subject being treated.
  • Single or multiple administrations e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more doses
  • an inhibitor may be administered in any suitable amount.
  • an inhibitor is administered to a subject within a range of about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 mg per week.
  • the inhibitor is administered to a subject within a range of about 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mg per week. In some embodiments, the inhibitor is administered to a subject within a range of about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mg per week.
  • an inhibitor is administered to a subject in an amount greater than 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 mg per day on average over the course of a treatment cycle.
  • the inhibitor is administered to a subject in an amount between about 6 and 10 mg, between about 6.5 and 9.5 mg, between about 6.5 and 8.5 mg, between about 6.5 and 8 mg, or between about 7 and 9 mg on average over the course of a treatment cycle.
  • an inhibitor is administered to a subject within a range of about 0.1 mg/kg-50 mg/kg per day, such as about, less than about, or more than about, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, or 50 mg/kg per day.
  • an inhibitor is administered to a subject within a range of about 0.1 mg/kg-400 mg/kg per week, such as about, less than about, or more than about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, or 400 mg/kg per week.
  • an inhibitor is administered to a subject within a range of about 0.1 mg/kg-1500 mg/kg per month, such as about, less than about, or more than about 50 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, or 1000 mg/kg per month.
  • an inhibitor is administered to a subject within a range of about 0.1 mg/m 2 -200 mg/m 2 per week, such as about, less than about, or more than about 5 mg/m 2 , 10 mg/m 2 , 15 mg/m 2 , 20 mg/m 2 , 25 mg/m 2 , 30 mg/m 2 , 35 mg/m 2 , 40 mg/m 2 , 45 mg/m 2 , 50 mg/m 2 , 55 mg/m 2 , 60 mg/m 2 , 65 mg/m 2 , 70 mg/m 2 , 75 mg/m 2 , 100 mg/m 2 , 125 mg/m 2 , 150 mg/m 2 , 175 mg/m 2 , or 200 mg/m 2 per week.
  • the target dose may be administered in a single dose.
  • the target dose may be administered in about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more doses.
  • a dose of about 20 mg/kg per week may be delivered weekly at a dose of about 20 mg/kg, or may be delivered at a dose of about 6.67 mg/kg administered on each of three days over the course of the week, which days may or may not be consecutive.
  • the administration schedule may be repeated according to any regimen according to the invention, including any administration schedule described herein.
  • an inhibitor is administered to a subject in the range of about 0.1 mg/m 2 -500 mg/m 2 , such as about, less than about, or more than about 5 mg/m 2 , 10 mg/m 2 ,15 mg/m 2 , 20 mg/m 2 , 25 mg/m 2 , 30 mg/m 2 , 35 mg/m 2 , 40 mg/m 2 , 45 mg/m 2 , 50 mg/m 2 , 55 mg/m 2 , 60 mg/m 2 , 65 mg/m 2 , 70 mg/m 2 , 75 mg/m 2 , 100 mg/m 2 , 130 mg/m 2 , 135 mg/m 2 , 155 mg/m 2 , 175 mg/m 2 , 200 mg/m 2 , 225 mg/m 2 , 250 mg/m 2 , 300 mg/m 2 , 350 mg/m 2 , 400 mg/m 2 , 420 mg/m 2 , 450 mg/m 2 , or 500 mg/m 2 .
  • a dose of mTorC1/mTorC2 inhibitor may be about, at least about, or at most about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000 mg or mg/kg, or any range derivable therein. It is contemplated that a dosage of mg/kg refers to the mg amount of inhibitor per kg of total body weight of the subject. It is contemplated that when multiple doses are given to a patient, the doses may vary in amount or they may be the same.
  • the amount of each inhibitor administered will be dependent on the mammal being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
  • An mTorC1/mTorC2 inhibitor for use in the present invention can be any mTorC1/mTorC2 inhibitor that is known in the art, and can include any chemical entity that, upon administration to a patient, results in inhibition of mTOR in the patient.
  • An mTorC1/mTorC2 inhibitor can inhibit mTorC1/mTorC2 by any biochemical mechanism, including competition at the ATP binding site, competition elsewhere at the catalytic site of mTOR kinase, non-competitive inhibition, irreversible inhibition (e.g.
  • inhibitors useful in the invention described herein include those disclosed and claimed in U.S. Pat. No. 7,700,594 and in U.S. Pat. No. 7,651,687, a series of compounds that inhibit mTOR by binding to and directly inhibiting both mTORC1 and mTORC2 kinases.
  • mTorC1/mTorC2 inhibitors that are dual PI3K/mTOR kinase inhibitors, such as for example the compound PI-103 as described in Fan, Q-W et al (2006) Cancer Cell 9:341-349 and Knight, Z. A. et al. (2006) Cell 125:733-747.
  • the capacity of an mTorC1/mTorC2 inhibitor to inhibit mTorC1/mTorC2 is expressed in terms of an IC50 value.
  • IC50 refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50).
  • EC50 refers to the plasma concentration required for obtaining 50% of a maximum effect in vivo.
  • Determination of IC50 can be made by determining and constructing a dose-response curve and examining the effect of different concentrations of an inhibitor on reversing agonist activity. In vitro assays that are useful in making these determinations are referred to as “in vitro kinase assays.”
  • an in vitro kinase assay includes the use of labeled ATP as phosphodonor, and following the kinase reaction the substrate peptide is captured on an appropriate filter. Unreacted labeled ATP and metabolites are resolved from the radioactive peptide substrate by various techniques, such as involving trichloroacetic acid precipitation and extensive washing. Addition of several positively charged residues allows capture on phosphocellulose paper followed by washing. Radioactivity incorporated into the substrate peptide is detected by scintillation counting.
  • This assay is relatively simple, reasonably sensitive, and the peptide substrate can be adjusted both in terms of sequence and concentration to meet the assay requirements.
  • Other exemplary kinase assays are detailed in U.S. Pat. No. 5,759,787 and U.S. application Ser. No. 12/728,926, both of which are incorporated herein by reference.
  • an mTorC1/mTorC2 inhibitor utilized in the subject methods to bind to and directly inhibit both mTORC1 and mTORC2 can be ascertained using any method known in the art or described herein.
  • inhibition of mTorC1 and/or mTorC2 activity can be determined by a reduction in signal transduction of the PI3K/Akt/mTor pathway.
  • readouts can be utilized to establish a reduction of the output of such signaling pathway.
  • Some non-limiting exemplary readouts include (1) a decrease in phosphorylation of Akt at residues, including but not limited to S473 and T308; (2) a decrease in activation of Akt as evidenced by a reduction of phosphorylation of Akt substrates including but not limited to FoxO1/O3a T24/32, GSK3 ⁇ / ⁇ S21/9, and TSC2 T1462; (3) a decrease in phosphorylation of signaling molecules downstream of mTor, including but not limited to ribosomal S6 S240/244, 70S6K T389, and 4EBP1 T37/46; (4) inhibition of proliferation of cells including but not limited to normal or neoplastic cells, mouse embryonic fibroblasts, leukemic blast cells, cancer stem cells, and cells that mediate autoimmune reactions; (5) induction of apoptosis of cells or cell cycle arrest (e.g. accumulation of cells in G1 phase); (6) reduction of cell chemotaxis; and (7) an increase in binding
  • mTOR exists in two types of complexes, mTorC1 containing the raptor subunit and mTorC2 containing rictor.
  • rictor refers to a cell growth regulatory protein having human gene locus 5p13.1. These complexes are regulated differently and have a different spectrum of substrates. For instance, mTor Cl phosphorylates S6 kinase (S6K) and 4EBP1, promoting increased translation and ribosome biogenesis to facilitate cell growth and cell cycle progression. S6K also acts in a feedback pathway to attenuate PI3K/Akt activation.
  • S6K S6 kinase
  • 4EBP1 S6 kinase
  • inhibition of mTor C 1 results in activation of 4EBP1, resulting in inhibition of (e.g. a decrease in) RNA translation.
  • mTorC2 is generally insensitive to rapamycin and selective inhibitors and is thought to modulate growth factor signaling by phosphorylating the C-terminal hydrophobic motif of some AGC kinases such as Akt.
  • Akt AGC kinases
  • mTorC2 is required for phosphorylation of the S473 site of Akt.
  • mTor Cl activity is partly controlled by Akt whereas Akt itself is partly controlled by mTorC2.
  • Akt Growth factor stimulation of PI3K causes activation of Akt by phosphorylation at the two key sites, S473 and T308. It has been reported that full activation of Akt requires phosphorylation of both S473 and T308Active. Akt promotes cell survival and proliferation in many ways including suppressing apoptosis, promoting glucose uptake, and modifying cellular metabolism. Of the two phosphorylation sites on Akt, activation loop phosphorylation at T308, mediated by PDK1, is believed to be indispensable for kinase activity, while hydrophobic motif phosphorylation at S473 enhances Akt kinase activity.
  • Inhibition of Akt phosphorylation can be determined using any methods known in the art or described herein. Representative assays include but are not limited to immunoblotting and immunoprecipitation with antibodies such as anti-phosphotyrosine antibodies that recognize the specific phosphorylated proteins. Cell-based ELISA kit quantifies the amount of activated (phosphorylated at S473) Akt relative to total Akt protein is also available (SuperArray Biosciences).
  • Selective mTor inhibition may also be determined by expression levels of the mTor genes, its downstream signaling genes (for example by RT-PCR), or expression levels of the proteins (for example by immunocytochemistry, immunohistochemistry, Western blots) as compared to other PI3-kinases or protein kinases.
  • Cell-based assays for establishing selective inhibition of mTorC1 and/or mTorC2 can take a variety of formats. This generally will depend on the biological activity and/or the signal transduction readout that is under investigation. For example, the ability of the agent to inhibit mTorC1 and/or mTorC2 to phosphorylate downstream substrate(s) can be determined by various types of kinase assays known in the art. Representative assays include but are not limited to immunoblotting and immunoprecipitation with antibodies such as anti-phosphotyrosine, anti-phosphoserine or anti-phosphothreonine antibodies that recognize phosphorylated proteins.
  • kinase activity can be detected by high throughput chemiluminescent assays such as AlphaScreenTM (available from Perkin Elmer) and eTagTM assay (Chan-Hui, et al. (2003) Clinical Immunology 111: 162-174).
  • single cell assays such as flow cytometry as described in the phosflow experiment can be used to measure phosphorylation of multiple downstream mTOR substrates in mixed cell populations.
  • One advantage of the immunoblotting and phosflow methods is that the phosphorylation of multiple kinase substrates can be measured simultaneously. This provides the advantage that efficacy and selectivity can be measured at the same time.
  • cells may be contacted with an mTorC1/mTorC2 inhibitor at various concentrations and the phosphorylation levels of substrates of both mTOR and other kinases can be measured.
  • a large number of kinase substrates are assayed in what is termed a “comprehensive kinase survey.”
  • Selective mTorC1/mTorC2 inhibitors are expected to inhibit phosphorylation of mTOR substrates without inhibiting phosphorylation of the substrates of other kinases.
  • selective mTorC1/mTorC2 inhibitors may inhibit phosphorylation of substrates of other kinases through anticipated or unanticipated mechanisms such as feedback loops or redundancy.
  • Non-limiting examples of cell proliferation assays include testing for tritiated thymidine uptake assays, BrdU (5′-bromo-2′-deoxyuridine) uptake (kit marketed by Calibochem), MTS uptake (kit marketed by Promega), MTT uptake (kit marketed by Cayman Chemical), CyQUANT® dye uptake (marketed by Invitrogen).
  • Apoptosis and cell cycle arrest analysis can be performed with any methods exemplified herein as well other methods known in the art. Many different methods have been devised to detect apoptosis. Exemplary assays include but are not limited to the TUNEL (TdT-mediated dUTP Nick-End Labeling) analysis, ISEL (in situ end labeling), and DNA laddering analysis for the detection of fragmentation of DNA in populations of cells or in individual cells, Annexin-V analysis that measures alterations in plasma membranes, detection of apoptosis related proteins such p53 and Fas.
  • TUNEL TdT-mediated dUTP Nick-End Labeling
  • ISEL in situ end labeling
  • DNA laddering analysis for the detection of fragmentation of DNA in populations of cells or in individual cells
  • Annexin-V analysis that measures alterations in plasma membranes
  • detection of apoptosis related proteins such p53 and Fas.
  • a cell-based assay typically proceeds with exposing the target cells (e.g., in a culture medium) to a test compound which is a potential mTorC1 and/or mTorC2 selective inhibitor, and then assaying for readout under investigation.
  • a test compound which is a potential mTorC1 and/or mTorC2 selective inhibitor
  • they can directly be added to the cells or in conjunction with carriers.
  • the agent when the agent is nucleic acid, it can be added to the cell culture by methods well known in the art, which include without limitation calcium phosphate precipitation, microinjection or electroporation.
  • the nucleic acid can be incorporated into an expression or insertion vector for incorporation into the cells.
  • Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Stratagene (La Jolla, Calif.) and Promega Biotech (Madison, Wis.). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5′ and/or 3′ untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation.
  • consensus ribosome binding sites can be inserted immediately 5′ of the start codon to enhance expression.
  • vectors are viruses, such as baculovirus and retrovirus, bacteriophage, adenovirus, adeno-associated virus, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
  • viruses such as baculovirus and retrovirus, bacteriophage, adenovirus, adeno-associated virus, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
  • non-viral vectors including DNA/liposome complexes, and targeted viral protein DNA complexes.
  • nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens.
  • Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention.
  • Other biologically acceptable carriers can be utilized, including those described in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (2000), in conjunction with the subject compounds. Additional methods for cell-based assays for determining effects of agents on cell-cycle progression are described in U.S. Pat. No. 7,612,189, incorporated herein by reference.
  • any cells that express PI3-kinase ⁇ , mTorC1, mTorC2 and/or Akt can be target cells.
  • specific cell types whose proliferation can be inhibited include fibroblast, cells of skeletal tissue (bone and cartilage), cells of epithelial tissues (e.g. liver, lung, breast, skin, bladder and kidney), cardiac and smooth muscle cells, neural cells (glia and neurones), endocrine cells (adrenal, pituitary, pancreatic islet cells), melanocytes, and many different types of haemopoietic cells (e.g., cells of B-cell or T-cell lineage, and their corresponding stem cells, lymphoblasts).
  • haemopoietic cells e.g., cells of B-cell or T-cell lineage, and their corresponding stem cells, lymphoblasts.
  • cells exhibiting a neoplastic propensity or phenotype are also of interest.
  • diseases involving abnormal functioning of genes include but are not limited to autoimmune diseases, cancer, obesity, hypertension, diabetes, neuronal and/or muscular degenerative diseases, cardiac diseases, endocrine disorders, and any combinations thereof.
  • the mTorC1/mTorC2 inhibitor utilized in the subject methods inhibits one of mTORC1 and mTORC2 selectively with an IC50 value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an in vitro kinase.
  • an mTorC1/mTorC2 inhibitor utilized in the subject methods inhibits mTORC1 selectively with an IC50 value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 200, 100, 75, 50, 25, 10, 5, 1 or 0.5 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 200, 100, 75, 50, 25, 10, 5, 1 or 0.5 nM or less as ascertained in an in vitro kinase assay. In one instance, the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay. As another example, the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay.
  • the present invention provides the use of an mTorC1/mTorC2 inhibitor, wherein the mTorC1/mTorC2 inhibitor directly binds to and inhibits one of mTORC1 and mTORC2 with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or
  • the present invention provides the use of an mTorC1/mTorC2 inhibitor, wherein the mTorC1/mTorC2 inhibitor directly binds to and inhibits both mTORC1 and mTORC2 with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro kinase assay.
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay, and the mTorC1/mTorC2 inhibitor is substantially inactive against one or more types I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 10 nM or less as ascertained in an in vitro kinase assay, and the mTorC1/mTorC2 inhibitor is substantially inactive against one or more types I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • substantially inactive refers to an inhibitor that inhibits the activity of its target by less than approximately 1%, 5%, 10%, 15% or 20% of its maximal activity in the absense of the inhibitor, as determined by an in vitro enzymatic assay (e.g. in vitro kinase assay).
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 2, 5, 10, 15, 20, 50, 100 or 100 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 1000, 500, 100, 75, 50, 25, 10, 5, 1, or 0.5 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 2, 5, 10, 15, 20, 50, 100 or 100 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits one of mTORC1 and mTORC2 with an IC50 value of about 50 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 100 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • the mTorC1/mTorC2 inhibitor inhibits both mTORC1 and mTORC2 with an IC50 value of about 50 nM or less as ascertained in an in vitro kinase assay, and said IC50 value is at least 5 times less than its IC50 value against all other type I PI3-kinases selected from the group consisting of PI3-kinase ⁇ , PI3-kinase ⁇ , PI3-kinase ⁇ , and PI3-kinase ⁇ .
  • mTorC1/mTorC2 inhibitors suitable for use in the subject methods can be selected from a variety types of molecules.
  • an inhibitor can be biological or chemical compound such as a simple or complex organic or inorganic molecule, peptide, peptide mimetic, protein (e.g. antibody), liposome, or a polynucleotide (e.g. small interfering RNA, microRNA, anti-sense, aptamer, ribozyme, or triple helix).
  • a polynucleotide e.g. small interfering RNA, microRNA, anti-sense, aptamer, ribozyme, or triple helix.
  • cancer cells may depend on overactive signaling for their survival (known as the oncogene addiction hypothesis). In this way, cancer cells are frequently observed to adapt to drug inhibition of an aberrant signaling component by selecting for mutations in the same pathway that overcome the effect of the drug. Therefore, cancer therapies may be more successful in overcoming the problem of drug resistance if they target a signaling pathway as a whole, or target more than one component within a signaling pathway.
  • Akt serine/threonine kinase
  • Akt possesses a protein domain known as a PH domain, or Pleckstrin Homology domain, which binds to phosphoinositides with high affinity.
  • PH domain protein domain
  • Pleckstrin Homology domain which binds to phosphoinositides with high affinity.
  • PIP3 phosphatidylinositol (3,4,5)-trisphosphate, PtdIns(3,4,5)P3
  • PIP2 phosphatidylinositol (3,4)-bisphosphate, PtdIns(3,4)P2).
  • PI3K phosphorylates PIP2 in response to signals from chemical messengers, such as ligand binding to G protein-coupled receptors or receptor tyrosine kinases. Phosphorylation by PI3K converts PIP2 to PIP3, recruiting Akt to the cell membrane where it is phosphorylated at serine 473 (S473) by mTORC2. Phosphorylation of Akt at another site, threonine 308 (T308), is not directly dependent on mTORC2, but requires PI3K activity. Therefore, PI3K activity towards Akt can be isolated from mTOR activity by examining Akt threonine 308 phosphorylation status in cells lacking mTORC2 activity.
  • the invention provides a compound which is an inhibitor of mTorC1/mTorC2 of the Formula I:
  • X 1 is N or C-E 1
  • X 2 is N or C
  • X 3 is N or C
  • X 4 is C—R 9 or N
  • X 5 is N or C-E 1
  • X 6 is C or N
  • X 7 is C or N; and wherein no more than two nitrogen ring atoms are adjacent;
  • R 1 is H, -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl, —C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylhetaryl, -L-C 1-10 alkylheterocylyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloalkyl, -L-C 2-10 alkynyl-C 3-8 cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocylyl, -L-heteroalkyl-
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • E 1 and E 2 are independently —(W 1 ) j —R 4 ;
  • M 1 is a 5, 6, 7, 8, 9, or -10 membered ring system, wherein the ring system is monocyclic or bicyclic, substituted with R 5 and additionally optionally substituted with one or more (W 2 ) k —R 2 ;
  • each k is 0 or 1;
  • j in E 1 or j in E 2 is independently 0 or 1;
  • W 1 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O
  • W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )S(O)——, —CH(R 7 )N(R 8 )S(O
  • R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 3 and R 4 are independently hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 3 )OR
  • R 5 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • each of R 31 , R 32 , and R 33 is independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or hetaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or hetaryl group is unsubstituted or is substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, hetaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;
  • each of R 7 and R 8 is independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, aryl, heteroaryl, heterocyclyl or C 3-10 cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R 6 ;
  • R 6 is halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, hetaryl-C 2-10 alkenyl, hetaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, hetero
  • R 9 is H, halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, hetaryl-C 1-10 alkyl, hetaryl-C 2-10 alkenyl, hetaryl-C 2-10 alkynyl, wherein each of said alkyl, al
  • M 1 is a 5, 6, 7, 8, 9, or -10 membered ring system, wherein the ring system is monocyclic or bicyclic.
  • the monocyclic M 1 ring is unsubstituted or substituted with one or more R 5 substituents (including 0, 1, 2, 3, 4, or 5 R 5 substituents).
  • the monocyclic M 1 ring is aromatic (including phenyl) or heteroaromatic (including but not limited to pyridinyl, pyrrolyl, imidazolyl, thiazolyl, or pyrimidinyl).
  • the monocyclic M 1 ring may be a 5 or 6 membered ring (including but not limited to pyridinyl, pyrrolyl, imidazolyl, thiazolyl, or pyrimidinyl).
  • M 2 is a five membered heteroaromatic group with one heteroatom, wherein the heteroatom is N, S, or O.
  • M 2 is a five membered heteroaromatic group with two heteroatoms, wherein the heteroatoms are nitrogen and oxygen or nitrogen and sulfur.
  • the bicyclic M 1 ring is unsubstituted or substituted with one or more R 5 substituents (including 0, 1, 2, 3, 4, 5, 6 or 7 R 5 substituents).
  • Bicyclic M 1 ring is a 7, 8, 9, or 10 membered aromatic or heteroaromatic.
  • Examples of an aromatic bicyclic M 1 ring include naphthyl.
  • the bicyclic M 1 ring is heteroaromatic and includes but is not limited to benzothiazolyl, quinolinyl, quinazolinyl, benzoxazolyl, and benzoimidazolyl.
  • the invention also provides compounds wherein M 1 is a moiety having a structure of Formula M1-A or Formula M1-B:
  • W 1 , W 2 , and W 7 are independently N or C—R 5 ;
  • W 4 and W 10 are independently N—R 5 , O, or S;
  • W 6 and W 8 are independently N or C—R 5 ;
  • W 5 and W 9 are independently N or C—R 2 ;
  • W 3 is C or N, provided no more than two N and/or N—R 5 are adjacent and no two O or S are adjacent.
  • the M 1 moiety of Formula M1-A is a moiety of Formula M1-A1, Formula M1-A2, Formula M1-A3, or Formula M1-A4:
  • W 4 is N—R 5 , O, or S; W 6 is N or C—R 5 and W 5 is N or C—R 2 .
  • M 1 moiety of Formula M1-A include:
  • R 5 is (W 1 ) k —R 53 or R 55 ; each k is independently 0 or 1, n is 0, 1, 2, or 3, and (W 1 ) k —R 53 and R 55 are as defined above.
  • the M 1 moiety of Formula M1-B is a moiety of Formula M1-B1, Formula M1-B2, Formula M1-B3, or Formula M1-B4:
  • W 10 is N—R 5 , O, or S
  • W 8 is N or C—R 5
  • W 5 is N or C—R 2 .
  • M 1 moiety of Formula M1-B include:
  • R′ 5 is (W 1 ) k —R 53 or R 55 ; k is 0 or 1, n is 0, 1, 2, or 3, and (W 1 ) k —R 53 and R 55 are as defined above.
  • the invention also provides compounds wherein M 1 is a moiety having a structure of Formula M1-C or Formula M1-D:
  • W 12 , W 13 , W 14 , and W 15 are independently N or C—R 5 ;
  • W 11 and W 18 are independently N—R 5 , O, or S;
  • W 16 and W 17 are independently N or C—R 5 ; provided no more than two N are adjacent.
  • the M 1 moiety of Formula M1-C or Formula M1-D is a moiety of Formula M1-C1 or Formula M1-D1:
  • W 11 and W 18 are N—R 5 , O, or S; and W 16 and W 17 are N or C—R 5 .
  • M 1 moiety of Formula M1-C and Formula M1-D include:
  • R′ 5 is (W 1 ) k —R 53 or R 55 ; k is 0 or 1, and (W 1 ) k —R 53 and R 55 are as defined above.
  • the invention also provides compounds wherein M 1 is a moiety having a structure of Formula M1-E:
  • X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , and X 17 are independently N, or C—R 5 ; provided that no more than two N are adjacent.
  • the M 1 moiety having a structure of Formula M1-E is a moiety having a structure of Formula M1-E1, M1-E2, M1-E3, M1-E4, M1-E5, M1-E6, M1-E7, or M1-E8:
  • the M 1 moiety having a structure of Formula M1-E is a moiety having a structure:
  • M 1 moiety of Formula M1-E include:
  • R′ 5 is (W 1 ) k —R 53 or R 55 ; k is 0 or 1, n is 0, 1, 2, or 3, and (W 1 ) k —R 53 or R 55 are as defined above. In some embodiments, k is 0, and R 5 is R 53 .
  • R 53 is hydrogen, unsubstituted or substituted C 1 -C 10 alkyl (which includes but is not limited to —CH 3 , —CH 2 CH 3 , n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, pentyl, hexyl, and heptyl), or unsubstituted or substituted C 3 -C 8 cycloalkyl (which includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl).
  • C 1 -C 10 alkyl which includes but is not limited to —CH 3 , —CH 2 CH 3 , n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, pentyl, hexyl, and heptyl
  • C 3 -C 8 cycloalkyl
  • R 53 is monocyclic or bicyclic aryl, wherein the R 53 aryl is unsubstituted or substituted. Some examples of aryl include but are not limited to phenyl, naphthyl or fluorenyl. In some other embodiments, R 53 is unsubstituted or substituted heteroaryl, including but not limited to monocyclic and bicyclic heteroaryl. Monocyclic heteroaryl R 53 includes but is not limited to pyrrolyl, thienyl, furyl, pyridinyl, pyranyl, imidazolyl, thiazolyl, pyrazolyl, and oxazolyl.
  • Bicyclic heteroaryl R 53 includes but is not limited to benzothiophenyl, benzofuryl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinazolinyl, azaindolyl, pyrazolopyrimidinyl, and purinyl.
  • R 53 may be alkylcycloalkyl (including but not limited to cyclopropylethyl, cyclopentylethyl, and cyclobutylpropyl), -alkylaryl (including but not limited to benzyl, phenylethyl, and phenylnaphthyl), -alkylhetaryl (including but not limited to pyridinylmethyl, pyrrolylethyl, and imidazolylpropyl), or -alkylheterocyclyl (non-limiting examples are morpholinylmethyl, 1-piperazinylmethyl, and azetidinylpropyl).
  • R 53 is unsubstituted or substituted C 2 -C 10 alkenyl (including but not limited to alkenyl such as, for example, vinyl, allyl, 1-methyl propen-1-yl, butenyl, or pentenyl) or unsubstituted or substituted alkynyl (including but not limited to unsubstituted or substituted C 2 -C 10 alkynyl such as acetylenyl, propargyl, butynyl, or pentynyl).
  • alkenyl including but not limited to alkenyl such as, for example, vinyl, allyl, 1-methyl propen-1-yl, butenyl, or pentenyl
  • unsubstituted or substituted alkynyl including but not limited to unsubstituted or substituted C 2 -C 10 alkynyl such as acetylenyl, propargyl, butynyl, or pentynyl.
  • R 53 wherein R 53 is alkenylaryl, alkenylheteroaryl, alkenylheteroalkyl, or alkenylheterocyclcyl, wherein each of alkenyl, aryl, heteroaryl, heteroalkyl, and heterocyclyl is as described herein and wherein the alkenylaryl, alkenylhetaryl, alkenylheteroalkyl, or alkenylheterocyclcyl moiety is attached to M 1 through the alkenyl.
  • R 53 is -alkynylaryl, -alkynylhetaryl, -alkynylheteroalkyl, -alkynylheterocylyl, -alkynylcycloalkyl, or -alkynylC 3-8 cycloalkenyl, wherein each of alkynyl, aryl, heteroaryl, heteroalkyl, and heterocyclyl is as described herein and wherein the alkynylaryl, alkynylhetaryl, alkynylheteroalkyl, or alkynylheterocycicyl moiety is attached to M 1 through the alkynyl.
  • R 53 is -alkoxyalkyl, -alkoxyalkenyl, or -alkoxyalkynyl, wherein each of alkoxy, alkyl, alkenyl, and alkynyl is as described herein and wherein the -alkoxyalkyl, -alkoxyalkenyl, or -alkoxyalkynyl moiety is attached to M 1 through the alkoxy.
  • R 53 is -heterocyclylalkyl, -heterocyclylalkenyl, or -heterocyclylalkynyl, wherein the heterocyclyl, alkyl, alkenyl, or alkynyl is as described herein and wherein the -heterocyclylalkyl, -heterocyclylalkenyl, or -heterocyclylalkynyl is attached to M 1 through the heterocyclyl portion of the moiety.
  • R 53 may be aryl-alkenyl, aryl-alkynyl, or aryl-heterocyclyl, wherein the aryl, alkenyl, alkynyl, or heterocyclyl is as described herein and wherein the aryl-alkenyl, aryl-alkynyl, or aryl-heterocyclyl moiety is attached to M 1 through the aryl portion of the moiety.
  • R 53 is heteroaryl-alkyl, heteroaryl-alkenyl, heteroaryl-alkynyl, heteroaryl-cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl -heterocyclyl, wherein each of heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, and heterocyclyl is as described herein and wherein the heteroaryl-alkyl, heteroaryl-alkenyl, heteroaryl-alkynyl, heteroaryl-cycloalkyl, heteroaryl-heteroalkyl, or heteroaryl-heterocyclyl moiety is attached to M 1 through the heteroaryl portion of the moiety.
  • the aryl or heteroaryl is unsubstituted or is substituted with one or more independent halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NNR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 ,
  • each of the alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moieties forming part of all of R 53 is unsubstituted or substituted with one or more halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —O-aryl, —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NNR 34 R 35 , or —C( ⁇ O)NR 31 R 32 substituents.
  • R 5 is —W 1 —R 53 .
  • R 5 is —OR 53 , including but not limited to Oalkyl (including but not limited to methoxy or ethoxy), —Oaryl (including but not limited to phenoxy), —O-heteroaryl (including but not limited to pyridinoxy) and —O-heterocycloxy(including but not limited to 4-N-piperidinoxy).
  • R 5 is —NR 6 R 53 including but not limited to anilinyl, diethylamino, and 4-N-piperidinylamino.
  • R 5 is —S(O) 0-2 R 53 , including but not limited to phenylsulfonyl and pyridinylsulfonyl.
  • the invention also provides compounds wherein R 5 is —C(O) (including but not limited to acetyl, benzoyl, and pyridinoyl) or —C(O)O R 53 (including but not limited to carboxyethyl, and carboxybenzyl).
  • R 5 is —C(O)N(R 6 )R 53 (including but not limited to C(O)NH(cyclopropyl) and C(O)N(Me)(phenyl)) or —CH(R 6 )N(R 7 )R 53 (including but not limited to —CH 2 —NH-pyrrolidinyl, CH 2 —NHcyclopropyl, and CH 2 -anilinyl).
  • R 5 is —N(R 6 )C(O)R 53 (including but not limited to —NHC(O)phenyl, —NHC(O)cyclopentyl, and to —NHC(O)piperidinyl) or —N(R 6 )S(O) 2 R 53 (including but not limited to —NHS(O) 2 phenyl, —NHS(O) 2 piperazinyl, and —NHS(O) 2 methyl.
  • R 5 is —N(R 6 )S(O)R 53 , —CH(R 6 )N(C(O)OR 7 ) R 53 , —CH(R 7 )N(C(O)R 7 ) R 53 , —CH(R 6 )N(SO 2 R 7 )R 53 , —CH(R 6 )N(R 7 )R 53 , —CH(R 6 )C(O)N(R 7 )R 53 , —CH(R 6 )N(R 7 )C(O)R 53 , —CH(R 6 )N(R 7 )S(O)R 53 , or —CH(R 6 )N(R 7 )S(O) 2 R 53 .
  • R 5 is R 55 .
  • R 55 is halo, —OH, —NO 2 , —CF 3 , —OCF 3 , or —CN.
  • R 55 is —R 31 , —OR 31 (including but not limited to methoxy, ethoxy, and butoxy)-C(O)R 31 (non-limiting examples include acetyl, propionyl, and pentanoyl), or —CO 2 R 31 (including but not limited to carboxymethyl, carboxyethyl and carboxypropyl).
  • R 55 is —NR 31 R 32 , —C( ⁇ O)NR 31 R 32 , —SO 2 NR 31 R 32 , or —S(O) 0-2 R 31 .
  • R 55 is —NR 34 R 35 or —SO 2 NR 34 R 35 , wherein R 34 R 35 are taken together with the nitrogen to which R 34 R 35 are attached to form a cyclic moiety.
  • the cyclic moiety so formed may be unsubstituted or substituted, wherein the substituents are selected from the group consisting of alkyl, —C(O)alkyl, —S(O) 2 alkyl, and —S(O) 2 aryl.
  • R 55 is —NR 31 C( ⁇ O)R 32 , NR 31 C( ⁇ O)OR 32 , NR 31 C( ⁇ O)NR 32 R 33 , NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , C( ⁇ O)SR 31 , NR 31 C( ⁇ NR 32 )NR 33 R 32 , NR 31 C( ⁇ NR 32 )OR 33 , NR 31 C( ⁇ NR 32 )SR 33 , —OC( ⁇ O)OR 33 , —OC( ⁇ O)NR 31 R 32 , —C( ⁇ O)NNR 34 R 35 , —OC( ⁇ O)SR 31 , —SC( ⁇ O)OR 31 , —P(O)OR 31 OR 32 , or —SC( ⁇ O)NR 31 R 32 .
  • R 55 is —NR 31 C( ⁇ O)R 32 , NR 31 C( ⁇ O)OR 32 , NR 31 C( ⁇ O)NR 32 R 33 , NR 31 S
  • the invention further provides a compound which is an mTorC1/mTorC2 inhibitor, wherein the compound has the Formula I-A:
  • X 1 is N or C-E 1 , X 2 is N, X 3 is C 1 and X 4 is C—R 9 or N; or X 1 is N or C-E 1 , X 2 is C, X 3 is N, and X 4 is C—R 9 or N;
  • R 1 is H, L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl-C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylheteroaryl, -L-C 1-10 alkylheterocyclyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloalkyl, -L-C 2-10 alkynyl-C 3-8 cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C 3-8 cycl
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • M 1 is a moiety having the structure of Formula M1-F1 or M1-F2:
  • k 0 or 1
  • E 1 and E 2 are independently —(W 1 ) j —R 4 ;
  • j in each instance (i.e., in E 1 or j in E 2 ), is independently 0 or 1
  • W 1 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O
  • W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )S(O)——, —CH(R 7 )N(R 8 )S(O
  • R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 3 and R 4 are independently hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF, —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33
  • R 5 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF, —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 , —NR
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;
  • R 7 and R 8 are each independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, aryl, heteroaryl, heterocyclyl or C 3-10 cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R 6 ;
  • R 6 is halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alkyny
  • R 9 is H, halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 ,
  • C( ⁇ O)NR 34 R 35 —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more independent halo, cyano, nitro, —OC 1-10 alkyl, C 1-10 alkyl, C 2-10 alken
  • X 4 is C—R 9 .
  • the invention also provides an inhibitor as defined above, wherein the compound is of Formula I:
  • the compound of Formula I-B or its pharmaceutically acceptable salt thereof is a compound having the structure of Formula I-B1 or Formula I-B2:
  • X 1 is N and X 2 is N. In other embodiments, X 1 is C-E 1 and X 2 is N. In yet other embodiments, X 1 is NH and X 2 is C. In further embodiments, X 1 is CH-E 1 and X 2 is C.
  • X 1 is N and X 2 is C. In further embodiments, X 1 is C-E 1
  • X 1 is C—(W 1 ) j —R 4 , where j is 0.
  • X 1 is CH. In yet another embodiment, X 1 is C-halogen, where halogen is Cl, F, Br, or I.
  • X 1 it is C—(W 1 ) j —R 4 .
  • W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • W 1 is —C(O)N(R 7 )—.
  • X 1 , j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of X 1 , j is 1, and W 1 is —C(O)O—. In various embodiments of X 1 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • X 1 is CH 2 . In yet another embodiment, X 1 is CH-halogen, where halogen is Cl, F, Br, or I.
  • X 1 is N.
  • X 2 is N. In other embodiments, X 2 is C.
  • E 2 is —(W 1 ) j —R 4 , where j is 0.
  • E 2 is CH. In yet another embodiment, E 2 is C-halogen, where halogen is Cl, F, Br, or I.
  • E 2 it is —(W 1 ) j —R 4 .
  • j is 1, and W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • j is 1, and W 1 is —C(O)N(R 7 )—.
  • E 2 j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of E 2 , j is 1, and W 1 is —C(O)O—. In various embodiments of E 2 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • M 1 when M 1 is a moiety of Formula M1-F1, M 1 is benzoxazolyl substituted with —(W 2 ) k —R 2 . In some embodiments, M 1 is a benzoxazolyl substituted at the 2-position with —(W 2 ) j —R 2 . In some embodiments, M 1 is either a 5-benzoxazolyl or a 6-benzoxazolyl moiety, optionally substituted at the 2-position with —(W 2 ) j —R 2 .
  • Exemplary Formula M1-F1 M 1 moieties include but are not limited to the following:
  • Formula M1-F2 is an aza-substituted benzoxazolyl moiety having a structure of one of the following formulae:
  • Exemplary Formula M1-F2 M 1 moieties include but are not limited to the following:
  • M 1 In various embodiments of M 1 , k is 0. In other embodiments of M 1 , k is 1, and W 2 is selected from one of the following: —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O) —, or —N(R 7 )C(O)N(R 8 ) —.
  • k is 1, and W 2 is —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 ) —, —CH(R 7 )N(C(O)R 8 ) —, or —CH(R 7 )N(SO 2 R 8 ) —.
  • k is 1, and W 2 is —CH(R 7 )N(R 8 ) —, —CH(R 7 )C(O)N(R 8 ) —, —CH(R 7 )N(R 8 )C(O) —, or —CH(R 7 )N(R 8 )S(O) —.
  • k is 1, and W 2 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • the invention provides an inhibitor of mTor which is a compound of Formula I-C or Formula I-D:
  • X 1 is N or C-E 1 , X 2 is N, and X 3 is C; or X 1 is N or C-E 1 , X 2 is C, and X 3 is N;
  • R 1 is H, L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl-C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylheteroaryl, -L-C 1-10 alkylheterocyclyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloalkyl, -L-C 2-10 alkynyl-C 3-8 cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C 3-8 cycl
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • E 1 and E 2 are independently —(W 1 ) j —R 4 ;
  • j in E 1 or j in E 2 is independently 0 or 1;
  • W 1 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O
  • W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )S(O)——, —CH(R 7 )N(R 8 )S(O
  • k 0 or 1
  • R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 3 and R 4 are independently hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR
  • R 5 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom; and
  • R 7 and R 8 are each independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, aryl, heteroaryl, heterocyclyl or C 3-10 cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R 6 ; and R 6 is halo, —OR 31 , —SH, NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, or C 2-10 alkynyl; or R 6 is aryl-C 1-10 alkyl,
  • the compound of Formula I-C has a structure of Formula I-C1 or Formula I-C2:
  • X 1 is N and X 2 is N. In other embodiments, X 1 is C-E 1 and X 2 is N. In yet other embodiments, X 1 is NH and X 2 is C. In further embodiments, X 1 is CH-E 1 and X 2 is C.
  • X 1 is N and X 2 is C. In yet other embodiments, X 1 is NH
  • X 1 is CH-E 1 and X 2 is C.
  • the compound of Formula I-D has a structure of Formula I-D1 or Formula I-D2:
  • X 1 is N and X 2 is N. In other embodiments, X 1 is C-E 1 and
  • X 2 is N. In yet other embodiments, X 1 is NH and X 2 is C. In further embodiments, X 1 is CH-E 1 and X 2 is C.
  • X 1 is N and X 2 is C. In further embodiments, X 1 is C-E 1
  • X 1 is C—(W 1 ) j —R 4 , where j is 0.
  • X 1 is CH. In yet another embodiment, X 1 is C-halogen, where halogen is Cl, F, Br, or I.
  • X 1 it is C—(W 1 ) j —R 4 .
  • W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • W 1 is —C(O)N(R 7 )—.
  • X 1 , j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of X 1 , j is 1, and W 1 is —C(O)O—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)OR 8 )—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • X 1 is CH—(W 1 ) j —R 4 , where j is 0.
  • X 1 is CH 2 . In yet another embodiment, X 1 is CH-halogen, where halogen is Cl, F, Br, or I.
  • X 1 it is CH—(W 1 ) j —R 4 .
  • W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • W 1 is —C(O)N(R 7 )—.
  • X 1 , j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of X 1 , j is 1, and W 1 is —C(O)O—. In various embodiments of X 1 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • X 1 is N.
  • X 2 is N. In other embodiments, X 2 is C.
  • E 2 is —(W 1 ) j —R 4 , where j is 0.
  • E 2 is CH. In yet another embodiment, E 2 is C-halogen, where halogen is Cl, F, Br, or I.
  • E 2 it is —(W 1 ) j —R 4 .
  • j is 1, and W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • j is 1, and W 1 is —C(O)N(R 7 )—.
  • E 2 j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of E 2 , j is 1, and W 1 is —C(O)O—. In various embodiments of E 2 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • k is 0. In other embodiments, k is 1 and W 2 is —O—. In another embodiment, k is 1 and W 2 is —NR 7 —. In yet another embodiment of, k is 1, and W 2 is —S(O) 0-2 —. In another embodiment of, k is 1 and W 2 is —C(O)—. In a further embodiment, k is 1 and W 2 is —C(O)N(R 7 ) —. In another embodiment, k is 1, and W 2 is —N(R 7 )C(O)—. In another embodiment, k is 1 and W 2 is —N(R 7 )C(O)—. In another embodiment, k is 1 and W 2 is —N(R 7 )C(O)N(R 8 )—.
  • k is 1 and W 2 is —N(R 7 )S(O)—. In still yet another embodiment, k is 1 and W 2 is —N(R 7 )S(O) 2 —. In a further embodiment, k is 1 and W 2 is —C(O)O—. In another embodiment, k is 1 and W 2 is —CH(R 7 )N(C(O)OR 8 )—. In another embodiment, k is 1 and W 2 is —CH(R 7 )N(C(O)R 8 )—. In another embodiment, k is 1 and W 2 is —CH(R 7 )N(SO 2 R 8 )—.
  • k is 1 and W 2 is —CH(R 7 )N(R 8 )—. In another embodiment, k is 1 and W 2 is —CH(R 7 )C(O)N(R 8 )—. In yet another embodiment, k is 1 and W 2 is —CH(R 7 )N(R 8 )C(O)—. In another embodiment, k is 1 and W 2 is —CH(R 7 )N(R 8 )S(O)—. In yet another embodiment, k is 1 and W 2 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • the invention also provides a compound which is an mTorC1/mTorC2 inhibitor of Formula I-E:
  • X 1 is N or C-E 1 , X 2 is N, and X 3 is C; or X 1 is N or C-E 1 , X 2 is C, and X 3 is N;
  • R 1 is —H, L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl-C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylheteroaryl, -L-C 1-10 alkylheterocyclyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloalkyl, -L-C 2-10 alkynyl-C 3-8 cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C 3-8
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • M 1 is a moiety having the structure of Formula M1-F1 or Formula M1-F2:
  • k 0 or 1
  • E 1 and E 2 are independently —(W 1 ) j —R 4 ;
  • j in E 1 or j in E 2 is independently 0 or 1;
  • W 1 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O
  • W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )S(O)——, —CH(R 7 )N(R 8 )S(O
  • R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 3 and R 4 are independently hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR
  • R 5 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;
  • R 7 and R 8 are each independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, aryl, heteroaryl, heterocyclyl or C 3-10 cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R 6 ;
  • R 6 is halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alkyny
  • R 9 is H, halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alky
  • the compound of Formula I-E has a structure of Formula I-E1 or Formula I-E2:
  • X 1 is N and X 2 is N. In other embodiments, X 1 is C-E 1 and X 2 is N. In yet other embodiments, X 1 is NH and X 2 is C. In further embodiments, X 1 is CH-E 1 and X 2 is C.
  • X 1 is N and X 2 is C. In further embodiments, X 1 is C-E 1
  • X 1 is C—(W 1 ) j —R 4 , where j is 0.
  • X 1 is CH. In yet another embodiment, X 1 is C-halogen, where halogen is Cl, F, Br, or I.
  • X 1 it is C—(W 1 ) j —R 4 .
  • W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • W 1 is —C(O)N(R 7 )—.
  • X 1 , j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of X 1 , j is 1, and W 1 is —C(O)O—. In various embodiments of X 1 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) —. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • X 1 is N.
  • X 2 is N. In other embodiments, X 2 is C.
  • E 2 is —(W 1 ) j —R 4 , where j is 0.
  • E 2 is CH. In yet another embodiment, E 2 is C-halogen, where halogen is Cl, F, Br, or I.
  • E 2 it is —(W 1 ) j —R 4 .
  • j is 1, and W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • j is 1, and W 1 is —C(O)N(R 7 )—.
  • E 2 j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of E 2 , j is 1, and W 1 is —C(O)O—. In various embodiments of E 2 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • M 1 when M 1 is a moiety of Formula I-E1, M 1 is benzoxazolyl substituted with —(W 2 ) k —R 2 . In some embodiments, M 1 is a benzoxazolyl moiety, substituted at the 2-position with —(W 2 ) k —R 2 . In some embodiments, M 1 is either a 5-benzoxazolyl or a 6-benzoxazolyl moiety, optionally substituted with —(W 2 ) k —R 2 .
  • Exemplary Formula I-E1 M 1 moieties include but are not limited to the following:
  • Formula I-E2 is an aza-substituted benzoxazolyl moiety having a structure of one of the following formulae:
  • Exemplary Formula I-E2 M 1 moieties include but are not limited to the following:
  • M 1 In various embodiments of M 1 , k is 0. In other embodiments of M 1 , k is 1 and W 2 is —O—. In another embodiment of M 1 , k is 1 and W 2 is —NR 7 —. In yet another embodiment of M 1 , k is 1 and W 2 is —S(O) 0-2 —. In another embodiment of M 1 , k is 1 and W 2 is —C(O)—. In a further embodiment of M 1 , k is 1 and W 2 is —C(O)N(R 7 ) —. In another embodiment of M 1 , k is 1 and W 2 is —N(R 7 )C(O)—.
  • k is 1 and W 2 is —N(R 7 )C(O)N(R 8 ) —.
  • k is 1 and W 2 is —N(R 7 )S(O) —.
  • k is 1 and W 2 is —N(R 7 )S(O) 2 —.
  • k is 1 and W 2 is —C(O)O—.
  • k is 1 and W 2 is —CH(R 7 )N(C(O)OR 8 ) —.
  • M 1 k is 1 and W 2 is —CH(R 7 )N(C(O)R 8 )—. In another embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )N(SO 2 R 8 )—. In a further embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )N(R 8 )—. In another embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )C(O)N(R 8 )—. In yet another embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )N(R 8 )C(O)—.
  • M 1 In another embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )N(R 8 )S(O) —. In yet another embodiment of M 1 , k is 1 and W 2 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • L is absent.
  • L is (C ⁇ O)—.
  • L is C( ⁇ O)O—.
  • L is —C( ⁇ O)NR 31 —.
  • L is —S—.
  • L is —S(O)—.
  • L is —S(O) 2 —.
  • L is —S(O) 2 NR 31 —.
  • L is —NR 31 —.
  • R 1 is L-C 1-10 alkyl, which is unsubstituted. In another embodiment, R 1 is L-C 1-10 alkyl, which is substituted by one or more independent R 3 . In yet another embodiment, R 1 is L-unsubstituted C 1-10 alkyl, where L is absent. In another embodiment, R 1 is L-C 1-10 alkyl, which is substituted by one or more independent R 3 , and L is absent.
  • R 1 is -L-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is L-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-C 3-8 cycloalkyl, which is unsubstituted, and L is absent.
  • R 1 is -L-C 3-8 cycloalkyl which is substituted by one or more independent R 3 , and L is absent.
  • R 1 is H.
  • R 1 is -L-aryl, which is unsubstituted. In another embodiment, R 1 is -L-aryl, which is substituted by one or more independent R 3 . In another embodiment, R 1 is -L-aryl which is unsubstituted, and L is absent. In yet another embodiment, R 1 is -L-aryl, which is substituted by one or more independent R 3 , and L is absent.
  • R 1 is -L-heteroaryl, which is unsubstituted.
  • R 1 is -L-heteroaryl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroaryl which is unsubstituted and L is absent.
  • R 1 is -L-heteroaryl, which is substituted by one or more independent R 3 , and L is absent.
  • R 1 is -L-C 1-10 alkyl-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is -L-C 1-10 alkyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-C 1-10 alkyl-C 3-8 cycloalkyl which is unsubstituted and L is absent.
  • R 1 is -L-C 1-10 alkyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 , and L is absent.
  • R 1 is -L-C 1-10 alkylaryl, which is unsubstituted.
  • R 1 is -L-C 1-10 alkylaryl, which is substituted by one or more independent R 3 .
  • R 1 is -L-C 1-10 alkylaryl which is unsubstituted and L is absent.
  • R 1 is -L-C 1-10 alkylaryl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 1-10 alkylheteroaryl, which is unsubstituted.
  • R 1 is -L-C 1-10 alkylheteroaryl, which is substituted by one or more independent R 3 .
  • R 1 is -L-C 1-10 alkylheteroaryl which is unsubstituted and L is absent.
  • R 1 is -L-C 1-10 alkylheteroaryl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 1-10 alkylheterocyclyl, which is unsubstituted.
  • R 1 is -L-C 1-10 alkylheterocyclyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-C 1-10 alkylheterocyclyl which is unsubstituted and L is absent.
  • R 1 is -L-C 1-10 alkylheterocyclyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 2-10 alkenyl, which is unsubstituted. In another embodiment, R 1 is -L-C 2-10 alkenyl which is substituted by one or more independent R 3 . In a further embodiment, R 1 is -L-C 2-10 alkenyl which is unsubstituted and L is absent. In yet another embodiment, R 1 is -L-C 2-10 alkenyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 2-10 alkynyl, which is unsubstituted. In another embodiment, R 1 is -L-C 2-10 alkynyl which is substituted by one or more independent R 3 . In a further embodiment, R 1 is -L-C 2-10 alkynyl which is unsubstituted and L is absent. In yet another embodiment, R 1 is -L-C 2-10 alkynyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 2-10 alkenyl-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is -L-C 2-10 alkenyl-C 3-8 cycloalkyl which is substituted by one or more independent R 3 .
  • R 1 is -L-C 2-10 alkenyl-C 3-8 cycloalkyl which is unsubstituted and L is absent.
  • R 1 is -L-C 2-10 alkenyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl which is substituted by one or more independent R 3 .
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl which is unsubstituted and L is absent.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl which is substituted by one or more independent R 3 .
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl which is unsubstituted and L is absent.
  • R 1 is -L-C 2-10 alkynyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroalkyl, which is unsubstituted. In another embodiment, R 1 is -L-heteroalkyl which is substituted by one or more independent R 3 . In a further embodiment, R 1 is -L-heteroalkyl which is unsubstituted and L is absent. In yet another embodiment, R 1 is -L-heteroalkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroalkylaryl, which is unsubstituted.
  • R 1 is -L-heteroalkylaryl which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroalkylaryl which is unsubstituted and L is absent.
  • R 1 is -L-heteroalkylaryl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroalkylheteroaryl, which is unsubstituted.
  • R 1 is -L-heteroalkylheteroaryl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroalkylheteroaryl which is unsubstituted and L is absent.
  • R 1 is -L-heteroalkylheteroaryl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroalkyl-heterocyclyl, which is unsubstituted.
  • R 1 is -L-heteroalkyl-heterocyclyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroalkyl-heterocyclyl which is unsubstituted, and L is absent.
  • R 1 is -L-heteroalkyl-heterocyclyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroalkyl-C 3-8 cycloalkyl, which is unsubstituted.
  • R 1 is -L-heteroalkyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroalkyl-C 3-8 cycloalkyl which is unsubstituted and L is absent.
  • R 1 is -L-heteroalkyl-C 3-8 cycloalkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-aralkyl, which is unsubstituted. In another embodiment, R 1 is -L-aralkyl, which is substituted by one or more independent R 3 . In a further embodiment, R 1 is -L-aralkyl which is unsubstituted. In yet another embodiment, R 1 is -L-aralkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heteroaralkyl, which is unsubstituted.
  • R 1 is -L-heteroaralkyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heteroaralkyl which is unsubstituted and L is absent.
  • R 1 is -L-heteroaralkyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is -L-heterocyclyl, which is unsubstituted.
  • R 1 is -L-heterocyclyl, which is substituted by one or more independent R 3 .
  • R 1 is -L-heterocyclyl which is unsubstituted and L is absent.
  • R 1 is -L-heterocyclyl, which is substituted by one or more independent R 3 , where L is absent.
  • R 1 is a substituent as shown below:
  • R 2 is hydrogen. In another embodiment, R 2 is halogen. In another embodiment, R 2 is —OH. In another embodiment, R 2 is —R 31 . In another embodiment, R 2 is —CF 3 . In another embodiment, R 2 is —OCF 3 . In another embodiment, R 2 is —OR 31 . In another embodiment, R 2 is —NR 31 R 32 . In another embodiment, R 2 is —NR 34 R 35 . In another embodiment, R 2 is —C(O)R 31 . In another embodiment, R 2 is —CO 2 R 31 . In another embodiment, R 2 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 2 is —C( ⁇ O)NR 34 R 35 .
  • R 2 is —NO 2 . In another embodiment, R 2 is —CN. In another embodiment, R 2 is —S(O) 0-2 R 3 . In another embodiment, R 2 is —SO 2 NR 31 R 32 . In another embodiment, R 2 is —SO 2 NR 34 R 35 . In another embodiment, R 2 is —NR 31 C( ⁇ O)R 32 . In another embodiment, R 2 is —NR 31 C( ⁇ O)OR 32 . In another embodiment, R 2 is —NR 31 C( ⁇ O)NR 32 R 33 . In another embodiment, R 2 is —NR 31 S(O) 0-2 R 32 . In another embodiment, R 2 is —C( ⁇ S)OR 31 . In another embodiment, R 2 is —C( ⁇ O)SR 31 . In another embodiment,
  • R 2 is —NR 31 C( ⁇ NR 32 )NR 33 R 32 . In another embodiment, R 2 is —NR 31 C( ⁇ NR 32 )OR 33 . In another embodiment, R 2 is —NR 31 C( ⁇ NR 32 )SR 33 . In another embodiment, R 2 is —OC( ⁇ O)OR 33 . In another embodiment, R 2 is —OC( ⁇ O)NR 31 R 32 . In another embodiment, R 2 is —OC( ⁇ O)SR 31 . In another embodiment, R 2 is —SC( ⁇ O)OR 31 . In another embodiment, R 2 is —P(O)OR 31 OR 32 . In another embodiment, R 2 is —SC( ⁇ O)NR 31 R 32 . In another embodiment, R 2 is monocyclic aryl.
  • R 2 is bicyclic aryl. In another embodiment, R 2 is substituted monocyclic aryl. In another embodiment, R 2 is heteroaryl. In another embodiment, R 2 is C 1-4 alkyl. In another embodiment, R 2 is C 1-10 alkyl. In another embodiment, R 2 is C 3-8 cycloalkyl. In another embodiment, R 2 is C 3-8 cycloalkyl-C 1-10 alkyl. In another embodiment, R 2 is C 1-10 alkyl-C 3-8 cycloalkyl. In another embodiment, R 2 is C 1-10 alkyl-monocyclic aryl. In another embodiment, R 2 is C 2-10 alkyl-monocyclic aryl.
  • R 2 is monocyclic aryl-C 2-10 alkyl. In another embodiment, R 2 is C 1-10 alkyl-bicyclicaryl. In another embodiment, R 2 is bicyclicaryl-C 1-10 alkyl. In another embodiment, R 2 is —C 1-10 alkylheteroaryl. In another embodiment, R 2 is —C 1-10 alkylheterocyclyl. In another embodiment, R 2 is —C 2-10 alkenyl. In another embodiment, R 2 is —C 2-10 alkynyl. In another embodiment, R 2 is C 2-10 alkenylaryl. In another embodiment, R 2 is C 2-10 alkenylheteroaryl.
  • R 2 is C 2-10 alkenylheteroalkyl. In another embodiment, R 2 is C 2-10 alkenylheterocyclcyl. In another embodiment, R 2 is —C 2-10 alkynylaryl. In another embodiment, R 2 is —C 2-10 alkynylheteroaryl. In another embodiment, R 2 is C 2-10 alkynylheteroalkyl. In another embodiment, R 2 is C 2-10 alkynylheterocyclyl. In another embodiment, R 2 is C 2-10 alkynylC 3-8 cycloalkyl. In another embodiment, R 2 is C 2-10 alkynylC 3-8 cycloalkenyl.
  • R 2 is C 1-10 alkoxy-C 1-10 alkyl. In another embodiment, R 2 is C 1-10 alkoxy-C 2-10 alkenyl. In another embodiment, R 2 is C 1-10 alkoxy-C 2-10 alkynyl. In another embodiment, R 2 is -heterocyclyl C 1-10 alkyl. In another embodiment, R 2 is heterocyclylC 2-10 alkenyl. In another embodiment, R 2 is heterocyclylC 2-10 alkynyl. In another embodiment, R 2 is arylC 2-10 alkyl. In another embodiment, R 2 is arylC 1-10 alkyl. In another embodiment, R 2 is arylC 2-10 alkenyl.
  • R 2 is arylC 2-10 alkynyl. In another embodiment, R 2 is aryl-heterocyclyl. In another embodiment, R 2 is heteroaryl C 1-10 alkyl. In another embodiment, R 2 is heteroarylC 2-10 alkenyl. In another embodiment, R 2 is heteroarylC 2-10 alkynyl. In another embodiment, R 2 is heteroaryl C 3-8 cycloalkyl. In another embodiment, R 2 is heteroaryl heteroalkyl. In another embodiment, R 2 is heteroaryl-heterocyclyl.
  • R 2 when R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is unsubstituted.
  • R 2 when R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent halo.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OH.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —R 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —CF 3 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OCF.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OR 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 34 R 35 .
  • R 4 when R 4 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C(O)R 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —CO 2 R 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)NR 31 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)NR 34 R 35 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NO 2 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —CN.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —S(O) 0-2 R 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SO 2 NR 31 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SO 2 NR 34 R 35 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)OR 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)NR 32 R 33 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 S(O) 0-2 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ S)OR 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)SR 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )NR 33 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent, —NR 31 C( ⁇ NR 32 )OR 33 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )SR 33 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)OR 33 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)NR 31 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)SR 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)OR 31 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —P(O)OR 31 OR 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)NR 31 R 32 .
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent alkyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent heteroalkyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent alkenyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent alkynyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent cycloalkyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent heterocycloalkyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent aryl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent arylalkyl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent heteroaryl.
  • R 2 is bicyclic aryl, monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, monocyclic aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent heteroarylalkyl.
  • R 3 is hydrogen. In another embodiment, R 3 is halogen. In another embodiment, R 3 is —OH. In another embodiment, R 3 is —R 31 . In another embodiment, R 3 is —CF 3 . In another embodiment, R 3 is —OCF 3 . In another embodiment, R 3 is —OR 31 . In another embodiment, R 3 is —NR 31 R 32 . In another embodiment, R 3 is —NR 34 R 35 . In another embodiment, R 3 is —C(O)R 31 . In another embodiment, R 3 is —CO 2 R 31 . In another embodiment, R 3 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 3 is —C( ⁇ O)NR 34 R 35 .
  • R 3 is —NO 2 . In another embodiment, R 3 is —CN. In another embodiment, R 3 is —S(O) 0-2 R 31 . In another embodiment, R 3 is —SO 2 NR 31 R 32 . In another embodiment, R 3 is —SO 2 NR 34 R 35 . In another embodiment, R 3 is —NR 31 C( ⁇ O)R 32 . In another embodiment, R 3 is —NR 31 C( ⁇ O)OR 32 . In another embodiment, R 3 is —NR 31 C( ⁇ O)NR 32 R 33 . In another embodiment, R 3 is —NR 31 S(O) 0-2 R 32 . In another embodiment, R 3 is —C( ⁇ S)OR 31 .
  • R 3 is —C( ⁇ O)SR 31 . In another embodiment, R 3 is —NR 31 C( ⁇ NR 32 )NR 33 R 32 . In another embodiment, R 3 is —NR 31 C( ⁇ NR 32 )OR 33 . In another embodiment, R 3 is —NR 31 C( ⁇ NR 32 )SR 33 . In another embodiment, R 3 is —OC( ⁇ O)OR 33 . In another embodiment, R 3 is —OC( ⁇ O)NR 31 R 32 . In another embodiment, R 3 is —OC( ⁇ O)SR 31 . In another embodiment, R 3 is —SC( ⁇ O)OR 31 . In another embodiment, R 3 is —P(O)OR 31 OR 32 .
  • R 3 is —SC( ⁇ O)NR 31 R 32 .
  • R 3 is aryl.
  • R 2 is heteroaryl.
  • R 3 is C 1-4 alkyl.
  • R 3 is C 1-10 alkyl.
  • R 3 is C 3-8 cycloalkyl.
  • R 3 is C 3-8 cycloalkyl-C 1-10 alkyl.
  • R 3 is —C 1-10 alkyl-C 3-8 cycloalkyl.
  • R 3 is C 2-10 alkyl-monocyclic aryl.
  • R 3 is monocyclic aryl-C 2-10 alkyl.
  • R 3 is C 1-10 alkyl-bicyclicaryl. In another embodiment, R 3 is bicyclicaryl-C 1-10 alkyl. In another embodiment, R 3 is C 1-10 alkylheteroaryl. In another embodiment, R 3 is C 1-10 alkylheterocyclyl. In another embodiment, R 3 is C 2-10 alkenyl. In another embodiment, R 3 is C 2-10 alkynyl. In another embodiment, R 3 is C 2-10 alkenylaryl. In another embodiment, R 3 is C 2-10 alkenylheteroaryl. In another embodiment, R 3 is C 2-10 alkenylheteroalkyl. In another embodiment, R 3 is C 2-10 alkenylheterocyclcyl.
  • R 3 is —C 2-10 alkynylaryl. In another embodiment, R 3 is —C 2-10 alkynylheteroaryl. In another embodiment, R 3 is —C 2-10 alkynylheteroalkyl. In another embodiment, R 3 is C 2-10 alkynylheterocyclyl. In another embodiment, R 3 is —C 2-10 alkynylC 3-8 cycloalkyl. In another embodiment, R 3 is C 2-10 alkynylC 3-8 cycloalkenyl. In another embodiment, R 3 is —C 1-10 alkoxy-C 1-10 alkyl. In another embodiment, R 3 is C 1-10 alkoxy-C 2-10 alkenyl.
  • R 3 is —C 1-10 alkoxy-C 2-10 alkynyl. In another embodiment, R 3 is heterocyclyl-C 1-10 alkyl. In another embodiment, R 3 is -heterocyclylC 2-10 alkenyl. In another embodiment, R 3 is heterocyclyl-C 2-10 alkynyl. In another embodiment, R 3 is aryl-C 1-10 alkyl. In another embodiment, R 3 is aryl-C 2-10 alkenyl. In another embodiment, R 3 is aryl-C 2-10 alkynyl. In another embodiment, R 3 is aryl-heterocyclyl. In another embodiment, R 3 is heteroaryl-C 1-10 alkyl.
  • R 3 is heteroaryl-C 2-10 alkenyl. In another embodiment, R 3 is heteroaryl-C 2-10 alkynyl. In another embodiment, R 3 is heteroaryl-C 3-8 cycloalkyl. In another embodiment, R 3 is heteroaryl heteroalkyl. In another embodiment, R 3 is heteroaryl-heterocyclyl.
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is unsubstituted. In another embodiment, when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent halo.
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —OH. In another embodiment, when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent R 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CF 3 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —OCF.
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent OR 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 31 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 34 R 35 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —C(O)R 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CO 2 R 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —C( ⁇ O)NR 31 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)NR 34 R 35 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NO 2 . In another embodiment, when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CN.
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —S(O) 0-2 R 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —SO 2 NR 31 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —SO 2 NR 34 R 35 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent NR 31 C( ⁇ O)R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)OR 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)NR 32 R 33 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 S(O) 0-2 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ S)OR 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)SR 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )NR 33 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent, —NR 31 C( ⁇ NR 32 )OR 33 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )SR 33 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)OR 33 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)NR 31 R 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)SR 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)OR 31 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —P(O)OR 31 OR 32 .
  • R 3 when R 3 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)NR 31 R 32 .
  • R 4 is hydrogen. In another embodiment, R 4 is halogen. In another embodiment, R 4 is —OH. In another embodiment, R 4 is —R 31 . In another embodiment, R 4 is —CF 3 . In another embodiment, R 4 is —OCF 3 . In another embodiment, R 4 is —OR 31 . In another embodiment, R 4 is —NR 31 R 32 . In another embodiment, R 4 is —NR 34 R 35 . In another embodiment, R 4 is —C(O)R 31 . In another embodiment, R 4 is —CO 2 R 31 . In another embodiment, R 4 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 4 is —C( ⁇ O)NR 34 R 35 .
  • R 4 is —NO 2 . In another embodiment, R 4 is —CN. In another embodiment, R 4 is —S(O) 0-2 R 31 . In another embodiment, R 4 is —SO 2 NR 31 R 32 . In another embodiment, R 4 is —SO 2 NR 34 R 35 . In another embodiment, R 4 is —NR 31 C( ⁇ O)R 32 . In another embodiment, R 4 is —NR 31 C( ⁇ O)OR 32 . In another embodiment, R 4 is —NR 31 C( ⁇ O)NR 32 R 33 . In another embodiment, R 4 is —NR 31 S(O) 0-2 R 32 . In another embodiment, R 4 is —C( ⁇ S)OR 31 .
  • R 4 is —C( ⁇ O)SR 31 . In another embodiment, R 4 is —NR 31 C( ⁇ NR 32 )NR 33 R 32 . In another embodiment, R 4 is —NR 31 C( ⁇ NR 32 )OR 33 . In another embodiment, R 4 is —NR 31 C( ⁇ NR 32 )SR 33 . In another embodiment, R 4 is —OC( ⁇ O)OR 33 . In another embodiment, R 4 is —OC( ⁇ O)NR 31 R 32 . In another embodiment, R 4 is —OC( ⁇ O)SR 31 . In another embodiment, R 4 is —SC( ⁇ O)OR 31 . In another embodiment, R 4 is —P(O)OR 31 OR 32 .
  • R 4 is —SC( ⁇ O)NR 31 R 32 .
  • R 4 is aryl.
  • R 4 is heteroaryl.
  • R 4 is C 1-4 alkyl.
  • R 4 is C 1-10 alkyl.
  • R 4 is C 3-8 cycloalkyl.
  • R 4 is C 1-10 alkyl-C 3-8 cycloalkyl.
  • R 4 is C 1-10 alkylaryl.
  • R 4 is C 1-10 alkylheteroaryl.
  • R 4 is C 1-10 alkylheterocyclyl.
  • R 4 is C 2-10 alkenyl.
  • R 4 is C 2-10 alkynyl. In another embodiment, R 4 is C 2-10 alkynyl-C 3-8 cycloalkyl. R 4 is C 2-10 alkenyl-C 3-8 cycloalkyl. In another embodiment, R 4 is C 2-10 alkenylaryl. In another embodiment, R 4 is C 2-10 alkenyl-heteroaryl. In another embodiment, R 4 is C 2-10 alkenylheteroalkyl. In another embodiment, R 4 is C 2-10 alkenylheterocyclcyl. In another embodiment, R 4 is —C 2-10 alkynylaryl. In another embodiment, R 4 is C 2-10 alkynylheteroaryl.
  • R 4 is C 2-10 alkynylheteroalkyl. In another embodiment, R 4 is C 2-10 alkynylheterocyclyl. In another embodiment, R 4 is C 2-10 alkynylC 3-8 cycloalkyl. In another embodiment, R 4 is heterocyclyl C 1-10 alkyl. In another embodiment, R 4 is heterocyclylC 2-10 alkenyl. In another embodiment, R 4 is heterocyclyl-C 2-10 alkynyl. In another embodiment, R 4 is aryl-C 1-10 alkyl. In another embodiment, R 4 is arylC 2-10 alkenyl. In another embodiment, R 4 is arylC 2-10 alkynyl.
  • R 4 is aryl-heterocyclyl. In another embodiment, R 4 is heteroaryl C 1-10 alkyl. In another embodiment, R 4 is heteroarylC 2-10 alkenyl. In another embodiment, R 4 is heteroarylC 2-10 alkynyl. In another embodiment, R 4 is C 3-8 cycloalkyl-C 1-10 alkyl. In another embodiment, R 4 is C 3-8 cycloalkyl-C 2-10 alkenyl. In another embodiment, R 4 is C 3-8 cycloalkyl-C 2-10 alkynyl.
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is unsubstituted. In another embodiment, when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent halo.
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —OH. In another embodiment, when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent R 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CF 3 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —OCF.
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —OR 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 31 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 34 R 35 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —C(O)R 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CO 2 R 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —C( ⁇ O)NR 31 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)NR 34 R 35 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NO 2 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —CN.
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —S(O) 0-2 R 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent SO 2 NR 31 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —SO 2 NR 34 R 35 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)OR 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ O)NR 32 R 33 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 S(O) 0-2 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ S)OR 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —C( ⁇ O)SR 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )NR 33 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent, —NR 31 C( ⁇ NR 32 )OR 33 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —NR 31 C( ⁇ NR 32 )SR 33 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)OR 33 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)NR 31 R 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —OC( ⁇ O)SR 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)OR 31 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, or heteroalkyl, it is substituted with one or more independent —P(O)OR 31 OR 32 .
  • R 4 when R 4 is aryl, heteroaryl, C 1-10 alkyl, cycloalkyl, heterocyclyl, heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl-C 2-10 alkyl, heterocyclyl C 1-10 alkyl, or C 3-8 cycloalkyl-C 1-10 alkyl, it is substituted with one or more independent —SC( ⁇ O)NR 31 R 32 .
  • R 5 is hydrogen. In another embodiment, R 5 is halogen. In another embodiment, R 5 is —OH. In another embodiment, R 5 is —R 31 . In another embodiment, R 5 is —CF 3 . In another embodiment, R 5 is —OCF 3 . In another embodiment, R 5 is —OR 31 . In another embodiment, R 5 is —NR 31 R 32 . In another embodiment, R 5 is —NR 34 R 35 . In another embodiment, R 5 is —C(O)R 31 . In another embodiment, R 5 is —CO 2 R 31 . In another embodiment, R 5 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 5 is —C( ⁇ O)NR 34 R 35 .
  • R 5 is —NO 2 . In another embodiment, R 5 is —CN. In another embodiment, R 5 is —S(O) 0-2 R 31 . In another embodiment, R 5 is —SO 2 NR 31 R 32 . In another embodiment, R 5 is —SO 2 NR 34 R 35 . In another embodiment, R 5 is —NR 31 C( ⁇ O)R 32 . In another embodiment, R 5 is —NR 31 C( ⁇ O)OR 32 . In another embodiment, R 5 is —NR 31 C( ⁇ O)NR 32 R 33 . In another embodiment, R 5 is —NR 31 S(O) 0-2 R 32 . In another embodiment, R 5 is —C( ⁇ S)OR 31 .
  • R 5 is —C( ⁇ O)SR 31 .
  • R 5 is —NR 31 C( ⁇ NR 32 )NR 33 R 32 .
  • R 5 is —NR 31 C( ⁇ NR 32 )OR 33 .
  • R 5 is —NR 31 C( ⁇ NR 32 )SR 33 .
  • R 5 is —OC( ⁇ O)OR 33 .
  • R 5 is —OC( ⁇ O)NR 31 R 32 .
  • R 5 is —OC( ⁇ O)SR 31 .
  • R 5 is —SC( ⁇ O)OR 31 .
  • R 5 is —P(O)OR 31 OR 32 .
  • R 5 is or —SC( ⁇ O)NR 31 R 32 .
  • R 7 is hydrogen. In another embodiment, R 7 is unsubstituted C 1-10 alkyl. In another embodiment, R 7 is unsubstituted C 2-10 alkenyl. In another embodiment, R 7 is unsubstituted aryl. In another embodiment, R 7 is unsubstituted heteroaryl. In another embodiment, R 7 is unsubstituted heterocyclyl. In another embodiment, R 7 is unsubstituted C 3-10 cycloalkyl. In another embodiment, R 7 is C 1-10 alkyl substituted by one or more independent R 6 . In another embodiment, R 7 is C 2-10 alkenyl substituted by one or more independent R 6 .
  • R 7 is aryl substituted by one or more independent R 6 . In another embodiment, R 7 is heteroaryl substituted by one or more independent R 6 . In another embodiment, R 7 is heterocyclyl substituted by one or more independent R 6 . In another embodiment, R 7 is C 3-10 cycloalkyl substituted by one or more independent R 6 .
  • R 8 is hydrogen. In another embodiment, R 8 is unsubstituted C 1-10 alkyl. In another embodiment, R 8 is unsubstituted C 2-10 alkenyl. In another embodiment, R 8 is unsubstituted aryl. In another embodiment, R 8 is unsubstituted heteroaryl. In another embodiment, R 8 is unsubstituted heterocyclyl. In another embodiment, R 8 is unsubstituted C 3-10 cycloalkyl. In another embodiment, R 8 is C 1-10 alkyl substituted by one or more independent R 6 . In another embodiment, R 8 is C 2-10 alkenyl substituted by one or more independent R 6 .
  • R 8 is aryl substituted by one or more independent R 6 . In another embodiment, R 8 is heteroaryl substituted by one or more independent R 6 . In another embodiment, R 8 is heterocyclyl substituted by one or more independent R 6 . In another embodiment, leis C 3-10 cycloalkyl substituted by one or more independent R 6 .
  • R 6 is halo, In another embodiment, R 6 is —OR 31 . In another embodiment, R 6 is —SH. In another embodiment, R 6 is NH 2 . In another embodiment, R 6 is —NR 34 R 35 . In another embodiment, R 6 is —NR 31 R 32 . In another embodiment, R 6 is —CO 2 R 31 . In another embodiment, R 6 is —CO 2 aryl. In another embodiment, R 6 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 6 is C( ⁇ O)NR 34 R 35 . In another embodiment, R 6 is —NO 2 . In another embodiment, R 6 is —CN.
  • R 6 is —S(O) 0-2 C 1-10 alkyl. In another embodiment, R 6 is —S(O) 0-2 aryl. In another embodiment, R 6 is —SO 2 NR 34 R 35 . In another embodiment, R 6 is —SO 2 NR 31 R 32 . In another embodiment, R 6 is C 1-10 alkyl. In another embodiment, R 6 is C 2-10 alkenyl. In another embodiment, R 6 is C 2-10 alkynyl. In another embodiment, R 6 is unsubstituted aryl-C 1-10 alkyl. In another embodiment, R 6 is unsubstituted aryl-C 2-10 alkenyl.
  • R 6 is unsubstituted aryl-C 2-10 alkynyl. In another embodiment, R 6 is unsubstituted heteroaryl-C 1-10 alkyl. In another embodiment, R 6 is unsubstituted heteroaryl-C 2-10 alkenyl. In another embodiment, R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent halo.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent cyano.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent nitro.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —OC 1-10 alkyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 1-10 alkyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 2-10 alkenyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 2-10 alkynyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 1-10 alkyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 2-10 alkenyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 2-10 alkynyl.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —COOH.
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C( ⁇ O)NR 31 R 32 .
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C( ⁇ O) NR 34 R 35 .
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —SO 2 NR 34 R 35 .
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —SO 2 NR 31 R 32 .
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —NR 31 R 32 .
  • R 6 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —NR 34 R 35 .
  • R 9 is H. In another embodiment, R 9 is halo. In another embodiment, R 9 is —OR 31 . In another embodiment, R 9 is —SH. In another embodiment, R 9 is NH 2 . In another embodiment, R 9 is —NR 34 R 35 . In another embodiment, R 9 is —NR 31 R 32 . In another embodiment, R 9 is —CO 2 R 31 . In another embodiment, R 9 is —CO 2 aryl. In another embodiment, R 9 is —C( ⁇ O)NR 31 R 32 . In another embodiment, R 9 is —C( ⁇ O)NR 34 R 35 . In another embodiment, R 9 is —NO 2 . In another embodiment, R 9 is —CN.
  • R 9 is —S(O) 0-2 C 1-10 alkyl. In another embodiment, R 9 is —S(O) 0-2 aryl. In another embodiment, R 9 is —SO 2 NR 34 R 35 . In another embodiment, R 9 is —SO 2 NR 31 R 32 . In another embodiment, R 9 is C 1-10 alkyl. In another embodiment, R 9 is C 2-10 alkenyl. In another embodiment, R 9 is C 2-10 alkynyl. In another embodiment, R 9 is unsubstituted aryl-C 1-10 alkyl. In another embodiment, R 9 is unsubstituted aryl-C 2-10 alkenyl.
  • R 9 is unsubstituted aryl-C 2-10 alkynyl. In another embodiment, R 9 is unsubstituted heteroaryl-C 1-10 alkyl. In another embodiment, R 9 is unsubstituted heteroaryl-C 2-10 alkenyl. In another embodiment, R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent halo.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent cyano.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent nitro.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —OC 1-10 alkyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 1-10 alkyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 2-10 alkenyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C 2-10 alkynyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 1-10 alkyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 2-10 alkenyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent -(halo)C 2-10 alkynyl.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —COOH.
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C( ⁇ O)NR 31 R 32 .
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —C( ⁇ O)NR 34 R 35 .
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —SO 2 NR 34 R 35 .
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —SO 2 NR 31 R 32 .
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —NR 31 R 32 .
  • R 9 is aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, or heteroaryl-C 2-10 alkenyl substituted by one or more independent —NR 34 R 35 .
  • R 31 is H. In some embodiments, R 31 is unsubstituted C 1-10 alkyl. In some embodiments, R 31 is substituted C 1-10 alkyl. In some embodiments, R 31 is C 1-10 alkyl substituted with one or more aryl. In some embodiments, R 31 is C 1-10 alkyl substituted with one or more heteroalkyl. In some embodiments, R 31 is C 1-10 alkyl substituted with one or more heterocyclyl. In some embodiments, R 31 is C 1-10 alkyl substituted with one or more heteroaryl.
  • each of said aryl substituents is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heteroalkyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heterocyclyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heteroaryl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(C 1
  • R 32 is H. In some embodiments, R 32 is unsubstituted C 1-10 alkyl. In some embodiments, R 32 is substituted C 1-10 alkyl. In some embodiments, R 32 is C 1-10 alkyl substituted with one or more aryl. In some embodiments, R 32 is C 1-10 alkyl substituted with one or more heteroalkyl. In some embodiments, R 32 is C 1-10 alkyl substituted with one or more heterocyclyl. In some embodiments, R 32 is C 1-10 alkyl substituted with one or more heteroaryl.
  • each of said aryl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(C 1
  • each of said heteroalkyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heterocyclyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heteroaryl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(C 1
  • R 33 is unsubstituted C 1-10 alkyl. In some embodiments, R 33 is substituted C 1-10 alkyl. In some embodiments, R 33 is C 1-10 alkyl substituted with one or more aryl. In some embodiments, R 33 is C 1-10 alkyl substituted with one or more heteroalkyl. In some embodiments, R 33 is C 1-10 alkyl substituted with one or more heterocyclyl. In some embodiments, R 33 is C 1-10 alkyl substituted with one or more heteroaryl.
  • each of said aryl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(C 1
  • each of said heteroalkyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heterocyclyl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(
  • each of said heteroaryl group is unsubstituted or substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —C 1-10 alkyl, —CO 2 —C 1-10 alkylaryl, —CO 2 -aryl, —C( ⁇ O)N(C 1-10 alkyl)(C 1-10 alkyl), —C( ⁇ O)NH(C 1
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.
  • the R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form:
  • X 1 is —C—NH 2 .
  • X 1 is C—NH—R 4 , where —NH—R 4 is:
  • the invention provides an inhibitor of Formula I-C1 where R 5 is H. In another embodiment, the invention provides an inhibitor of Formula I-C2 where R 5 is H.
  • the invention provides an inhibitor of Formula I-C1a:
  • E 2 is —H
  • X 1 and X 2 are N;
  • R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 ;
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —(C ⁇ O)N(R 31 )—, —S—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • R 3 is hydrogen, —OH, —OR 31 , —NR 31 R 32 , —C(O)R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , aryl, heteroaryl, C 1-4 alkyl, C 1-10 alkyl, C 3-8 cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(
  • —(W 2 ) k — is —NH—, —N(H)C(O)— or —N(H)S(O) 2 —;
  • R 2 is hydrogen, halogen, —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , bicyclic aryl, substituted monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 1-10 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, C 3-8 cycloalkyl-C 2-10 alkenyl, C 3-8 cycloalkyl-C 2-10 alkynyl, C 2-10 alkyl-monocyclic aryl, monocyclic aryl-C 2-10 alkyl, C 1-10 alkylbic
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted;
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.
  • an inhibitor of Formula I-C1 is a compound of Formula I-C1a:
  • R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 ;
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • R 3 is hydrogen, —OH, —OR 31 , —NR 31 R 32 , —C(O)R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , aryl, heteroaryl, C 1-4 alkyl, C 1-10 alkyl, C 3-8 cycloalkyl, or heterocyclyl, wherein each of said aryl or heteroaryl moiety is unsubstituted or is substituted with one or more independent alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, —OH, R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O
  • —(W 2 ) k — is —NH—, —N(H)C(O)— or —N(H)S(O) 2 —;
  • R 2 is hydrogen, halogen, —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , bicyclic aryl, substituted monocyclic aryl, heteroaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 1-10 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-10 alkyl, C 2-10 alkyl-monocyclic aryl, monocyclic aryl-C 2-10 alkyl, C 1-10 alkylbicycloaryl, bicycloaryl-C 1-10 alkyl, substituted C 1-10 alkylaryl, substituted aryl-C 1-10
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted;
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen.
  • the invention further provides a compound which is an mTorC1/mTorC2 inhibitor, wherein the compound has the Formula I-A:
  • X 1 is N or C-E 1 , X 2 is N, X 3 is C, and X 4 is C—R 9 or N; or X 1 is N or C-E 1 , X 2 is C, X 3 is N, and X 4 is C—R 9 or N;
  • R 1 is —H, -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkyl-C 3-8 cycloalkyl, -L-aryl, -L-heteroaryl, -L-C 1-10 alkylaryl, -L-C 1-10 alkylheteroaryl, -L-C 1-10 alkylheterocyclyl, -L-C 2-10 alkenyl, -L-C 2-10 alkynyl, -L-C 2-10 alkenyl-C 3-8 cycloalkyl, -L-C 2-10 alkynyl-C 3-8 cycloalkyl, -L-heteroalkyl, -L-heteroalkylaryl, -L-heteroalkylheteroaryl, -L-heteroalkyl-heterocyclyl, -L-heteroalkyl-C
  • L is absent, —(C ⁇ O)—, —C( ⁇ O)O—, —C( ⁇ O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;
  • M 1 is benzothiazolyl substituted with —(W 2 ) k —R 2 ;
  • k 0 or 1
  • E 1 and E 2 are independently —(W 1 ) j —R 4 ;
  • j in each instance (i.e., in E 1 or j in E 2 ), is independently 0 or 1
  • W 1 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O
  • W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )S(O)——, —CH(R 7 )N(R 8 )S(O
  • R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 3 and R 4 are independently hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR
  • R 5 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C( ⁇ O)NR 31 R 32 , —C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C( ⁇ O)R 32 , —NR 31 C( ⁇ O)OR 32 , —NR 31 C( ⁇ O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C( ⁇ S)OR 31 , —C( ⁇ O)SR 31 , —NR 31 C( ⁇ NR 32 )NR 33 R 32 , —NR 31 C( ⁇ NR 32 )OR 33 ,
  • R 31 , R 32 , and R 33 are independently H or C 1-10 alkyl, wherein the C 1-10 alkyl is unsubstituted or is substituted with one or more aryl, heteroalkyl, heterocyclyl, or heteroaryl group, wherein each of said aryl, heteroalkyl, heterocyclyl, or heteroaryl group is unsubstituted or is substituted with one or more halo, —OH, —C 1-10 alkyl, —CF 3 , —O-aryl, —OCF 3 , —OC 1-10 alkyl, —NH 2 , —N(C 1-10 alkyl)(C 1-10 alkyl), —NH(C 1-10 alkyl), —NH(aryl), —NR 34 R 35 , —C(O)(C 1-10 alkyl), —C(O)(C 1-10 alkyl-aryl), —C(O)(aryl), —CO 2 —
  • R 34 and R 35 in —NR 34 R 35 , —C( ⁇ O)NR 34 R 35 , or —SO 2 NR 34 R 35 are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 , hydroxyl, halogen, oxo, aryl, heteroaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom;
  • R 7 and R 8 are each independently hydrogen, C 1-10 alkyl, C 2-10 alkenyl, aryl, heteroaryl, heterocyclyl or C 3-10 cycloalkyl, each of which except for hydrogen is unsubstituted or is substituted by one or more independent R 6 ;
  • R 6 is halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alkyny
  • R 9 is H, halo, —OR 31 , —SH, —NH 2 , —NR 34 R 35 , —NR 31 R 32 , —CO 2 R 31 , —CO 2 aryl, —C( ⁇ O)NR 31 R 32 , C( ⁇ O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 C 1-10 alkyl, —S(O) 0-2 aryl, —SO 2 NR 34 R 35 , —SO 2 NR 31 R 32 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl; aryl-C 1-10 alkyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, heteroaryl-C 1-10 alkyl, heteroaryl-C 2-10 alkenyl, heteroaryl-C 2-10 alkynyl, wherein each of said alkyl, alkenyl, alky
  • X 4 is C—R 9 .
  • the invention also provides an inhibitor as defined above, wherein the compound is of Formula I-B:
  • the compound of Formula I-B or its pharmaceutically acceptable salt thereof is an inhibitor having the structure of Formula I-B1 or Formula I-B2:
  • X 1 is N and X 2 is N. In other embodiments, X 1 is C-E 1 and X 2 is N. In yet other embodiments, X 1 is NH and X 2 is C. In further embodiments, X 1 is CH-E 1 and X 2 is C.
  • X 1 is N and X 2 is C. In further embodiments, X 1 is C-E 1
  • X 1 is C—(W 1 ) j —R 4 , where j is 0.
  • X 1 is CH. In yet another embodiment, X 1 is C-halogen, where halogen is Cl, F, Br, or I.
  • X 1 it is C—(W 1 ), —R 4 .
  • W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • W 1 is —C(O)N(R 7 )—.
  • X 1 , j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of X 1 , j is 1, and W 1 is —C(O)O—. In various embodiments of X 1 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of X 1 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • X 1 is CH 2 . In yet another embodiment, X 1 is CH-halogen, where halogen is Cl, F, Br, or I.
  • X 1 is N.
  • X 2 is N. In other embodiments, X 2 is C.
  • E 2 is —(W 1 ) j —R 4 , where j is 0.
  • E 2 is CH. In yet another embodiment, E 2 is C-halogen, where halogen is Cl, F, Br, or I.
  • E 2 it is —(W 1 ) j —R 4 .
  • j is 1, and W 1 is —O—.
  • W 1 is —NR 7 —.
  • W 1 is —NH—.
  • W 1 is —S(O) 0-2 —.
  • W 1 is —C(O)—.
  • j is 1, and W 1 is —C(O)N(R 7 )—.
  • E 2 j is 1, and W 1 is —N(R 7 )C(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —N(R 7 )S(O) 2 —. In various embodiments of E 2 , j is 1, and W 1 is —C(O)O—. In various embodiments of E 2 , j is 1, and W 1 is CH(R 7 )N(C(O)OR 8 )—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(C(O)R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(SO 2 R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )C(O)N(R 8 )—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )C(O)—.
  • E 2 j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O)—. In various embodiments of E 2 , j is 1, and W 1 is —CH(R 7 )N(R 8 )S(O) 2 —.
  • M 1 is:
  • M 1 is benzothiazolyl substituted with —(W 2 ) k —R 2 .
  • W 2 can be —O—, —S(O) 0-2 — (including but not limited to S—, —S(O)—, and S(O) 2 —), —C(O), or C(O)O—.
  • W 1 is —NR 6 — or —CH(R 6 )N(R 7 )—, wherein R 6 and R 7 are each independently hydrogen, unsubstituted or substituted C 1 -C 10 alkyl (which includes but is not limited to —CH 3 , —CH 2 CH 3 , n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, pentyl, hexyl, and heptyl), unsubstituted or substituted C 2 -C 10 alkenyl (including but not limited to alkenyl such as, for example, vinyl, allyl, 1-methyl propen-1-yl, butenyl, or pentenyl).
  • C 1 -C 10 alkyl which includes but is not limited to —CH 3 , —CH 2 CH 3 , n-propyl, isopropyl, n-butyl, tert-butyl, sec-but
  • R 6 and R 7 are each independently unsubstituted or substituted aryl (including phenyl and naphthtyl).
  • R 6 and R 7 are each independently heteroaryl, wherein the heteroaryl is unsubstituted or substituted.
  • R 6 and R 7 heteroaryl is monocyclic heteroaryl, and includes but is not limited to imidazolyl, pyrrolyl, oxazolyl, thiazolyl, and pyridinyl.
  • R 6 and R 7 are each independently unsubstituted or substituted heterocyclyl (which includes but is not limited to pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, thiazolidinyl, imidazolidinyl, morpholinyl, and piperazinyl) or unsubstituted or substituted C 3-8 cycloalkyl (including but not limited to cyclopropyl, cyclobutyl, and cyclopentyl).
  • Non exemplary W 2 include —NH—, —N(cyclopropyl), and —N(4-N-piperidinyl).
  • exemplary mTorC1/mTorC2 inhibitors of the invention have the Formulas:
  • the compounds for use in the invention are chosen from the group consisting of:
  • mTorC1/mTorC2 inhibitor compounds disclosed herein may be prepared by the routes described below. Materials used herein are either commercially available or prepared by synthetic methods generally known in the art. These schemes are not limited to the compounds listed or by any particular substituents employed for illustrative purposes. Numbering does not necessarily correspond to that of claims or other tables.
  • compounds are synthesized by condensing a functionalized heterocycle A-1 with formamide, to provide a pyrazolopyrimidine A-2.
  • the pyrazolopyrimidine is treated with N-iodosuccinimide, which introduces an iodo substituent in the pyrazole ring as in A-3.
  • the R 1 substituent is introduced by reacting the pyrazolopyrimidine A3 with a compound of Formula R 1 -Lg in the presence of a base such as potassium carbonate to produce a compound of Formula A-4.
  • bases that are suitable for use in this step include but are not limited to sodium hydride and potassium t-butoxide.
  • the compound of Formula R 1 -Lg has a moiety R 1 as defined for R 1 of a compound of Formula I-A, and wherein Lg is an appropriate leaving group such as halide (including bromo, iodo, and chloro), tosylate, or other suitable leaving group,
  • Mitsunobu chemistry can be used to obtain alkylated pyrazolopyrimidine A-4, as shown in Scheme A-1.
  • Iodopyrazolopyrimidine A-3 is reacted with a suitable alcohol, in the presence of triphenylphosphine and diisopropylazodicarboxylate (DIAD) to produce pyrazolopyrimidine A-4.
  • DIAD diisopropylazodicarboxylate
  • the compounds of the invention may be synthesized via a reaction scheme represented generally in Scheme B.
  • the synthesis proceeds via coupling a compound of Formula A with a compound of Formula B to yield a compound of Formula C.
  • the coupling step is typically catalyzed by using, e.g., a palladium catalyst, including but not limited to palladium tetrakis (triphenylphosphine).
  • the coupling is generally performed in the presence of a suitable base, a nonlimiting example being sodium carbonate.
  • a suitable solvent for the reaction is aqueous dioxane.
  • a compound of Formula A for use in Scheme B has a structure of Formula A, wherein T 1 is triflate or halo (including bromo, chloro, and iodo), and wherein R 1 , X 1 , X 2 , X 3 , R 31 and R 32 are defined as for a compound of Formula I-A.
  • M is either M 1 or M 2 .
  • M 1 is defined as for a compound of Formula I-A.
  • M 1 can be a 5-benzoxazolyl or a 6-benzoxazolyl moiety, including but not limited to those M 1 moieties disclosed herein.
  • M 2 is a moiety which is synthetically transformed to form M 1 , after the M 2 moiety has been coupled to the bicyclic core of the compound of Formula A.
  • G is hydrogen or R G1 , wherein R G1 is alkyl, alkenyl, or aryl.
  • B(OG) 2 is taken together to form a 5- or 6-membered cyclic moiety.
  • the compound of Formula B is a compound having a structure of Formula E:
  • G is H or R G1 ;
  • R G1 is alkyl, alkenyl, or aryl.
  • R 2 is a R G2 moiety, wherein the R G2 moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxycarbonyl (FMOC), p-methoxybenzyl (PMB), and the like.
  • R G2 moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxycarbonyl (FMOC), p-methoxybenzyl (PMB), and the like.
  • a compound of Formula B is a compound of Formula B′, wherein G is R G1 . or a compound of Formula B′′, wherein G is hydrogen.
  • Scheme C depicts an exemplary scheme for synthesizing a compound of Formula B′ or, optionally, Formula B′′ for use in Reaction Scheme C.
  • This reaction proceeds via reacting a compound of Formula D with a trialkyl borate or a boronic acid derivative to produce a compound of Formula B′.
  • the reaction is typically run a solvent such as dioxane or tetrahydrofuran.
  • the trialkyl borate includes but is not limited to triisopropyl borate and the boronic acid derivative includes but is not limited to bis(pinacolato)diboron.
  • a base such as n-butyllithium is first added to the compound of Formula D to generate an anion, prior to the addition of the borate.
  • a boronic acid derivative such as bis(pinacolato)diboron
  • a palladium catalyst and a base is used.
  • Typical palladium catalysts include but is not limited to palladium chloride (diphenylphosphino)ferrocene).
  • a suitable base includes but is not limited to potassium acetate.
  • a compound of Formula D for use in Scheme C is a compound wherein T 2 is halo or another leaving group, and M is as defined above in Scheme B.
  • the compound of Formula B′ may further be converted to a compound of Formula B′′ by treatment with an acid such as hydrochloric acid.
  • the G groups are hydrogen. In another of a compound of Formula B, B′, B′′, or E, the G groups are R G1 .
  • no further synthetic transformation of M 1 moiety is performed after the coupling reaction when, e.g. M 1 is 2-N-acetyl-benzoxazol-5-yl.
  • a compound of Formula E is synthesized from a compound of Formula F, as shown in Scheme C-1:
  • Scheme C-1 depicts an exemplary scheme for synthesizing a compound of Formula E. This reaction proceeds via reacting a compound of Formula F with a trialkyl borate or a boronic acid derivative to produce a compound of Formula E. The conditions of the reaction are as described above in Scheme C.
  • a compound of Formula F for use in Scheme C-1 is a compound wherein T 2 is halo (including Br, Cl, and I) or another leaving group (including but not limited to triflate, tosylate, and mesylate), and the G p moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxycarbonyl (FMOC), p-methoxybenzyl (PMB), and the like.
  • T 2 is halo (including Br, Cl, and I) or another leaving group (including but not limited to triflate, tosylate, and mesylate)
  • the G p moiety is H, acyl, or an amino protecting group including but not limited to tert-butyl carbamate (Boc), carbobenzyloxy (Cbz), benzyl (Bz), fluorenylmethyloxy
  • the compound of Formula E, wherein G is alkyl may further be converted to a compound of Formula E, wherein G is hydrogen, by treatment with an acid such as hydrochloric acid
  • deprotection of a substituent e.g., removal of Boc protection from an amino substituent
  • M 1 of Formula C benzoxazolyl moiety
  • Some exemplary compounds with such protecting groups include but are not limited to compounds of the following formulae:
  • Step 1 a compound of Formula 3-1 is reacted with boronic acid 3-2, in the presence of palladium tetrakis (triphenylphosphine) and a suitable base, such as sodium carbonate in an aqueous/organic solvent mixture to produce a compound of Formula 3-3.
  • Step 2 the compound of Formula 3-3 is reacted with about 2 equivalents of nitric acid in acetic acid as solvent to produce a compound of Formula 3-4.
  • Two alternative transformations may be used to effect the next transformation of Step 3.
  • the compound of Formula 3-4 is treated with sodium dithionite and sodium hydroxide in water to produce a compound of Formula 3-5.
  • the compound of Formula 3-4 is reduced using palladium on carbon in a suitable solvent under a hydrogen atmosphere to yield a compound of Formula 3-5.
  • Step 4 compound 3-5 is reacted with about 1.2 equivalents of cyanogen bromide in a solvent such as methanol/tetrahydrofuran mixture to produce a compound of Formula 3-6.
  • a solvent such as methanol/tetrahydrofuran mixture
  • the compound of Formula 3-6 may be further transformed by other substitution or derivatization.
  • a compound of Formula 3-1 useful in the method of Scheme D is a compound having a structure of Formula 3-1, wherein T 1 is triflate or halo (including bromo, chloro, and iodo), and wherein R 1 , X 1 , X 2 , X 3 , R 31 and R 32 are defined as for a compound of Formula I-A.
  • Exemplary compounds having a pyrazolopyrimidine core can be synthesized via Scheme E.
  • Step 1 of Scheme E compound A-2 in dimethylformamide (DMF), is reacted with an N-halosuccinimide (NT 1 S) at about 80° C., to provide compound 4-1, where T 1 is iodo or bromo.
  • NT 1 S N-halosuccinimide
  • Step 2 compound 4-1 in DMF is reacted with a compound R 1 T x , in the presence of potassium carbonate, to provide compound 4-2.
  • compound 4-2 is coupled with a compound of Formula B using palladium catalysis such as palladium tetrakis (triphenylphosphine), and in the presence of sodium carbonate, to yield a pyrazolopyrimidine compound as shown.
  • a compound of Formula R 1 T x suitable for use in Reaction Scheme E is the compound wherein R 1 is cycloalkyl or alkyl and T x is halo (including bromo, iodo, or chloro) or a leaving group, including but not limited to mesylate or tosylate.
  • Reaction Schemes F-M illustrate methods of synthesis of borane reagents useful in preparing intermediates of use in synthesis of the compounds of the invention as described in Reaction Schemes A, B, and E above, to introduce M 1 substituents.
  • a compound of Formula N-1 and a compound of N-2 are coupled to produce a compound of Formula C.
  • the coupling step is typically catalyzed by using, e.g., a palladium catalyst, including but not limited to palladium tetrakis (triphenylphosphine).
  • the coupling is generally performed in the presence of a suitable base, a nonlimiting example being sodium carbonate.
  • a suitable base a nonlimiting example being sodium carbonate.
  • a suitable solvent for the reaction is aqueous dioxane.
  • a compound of Formula N-1 for use in Scheme N has a structure of Formula N-1, wherein G is hydrogen or R G1 , wherein R G1 is alkyl, alkenyl, or aryl.
  • B(OG) 2 of the compound of Formula N-1 is taken together to form a 5- or 6-membered cyclic moiety.
  • R 1 , X 1 , X 2 , X 3 , R 31 and R 32 of the compound of Formula N-1 are defined as for a compound of Formula I-A.
  • a compound of Formula N-2 for use in Scheme N has a structure of Formula N-2 wherein T 1 is triflate or halo (including bromo, chloro, and iodo).
  • M of the compound of Formula N-2 is either M 1 or M 2 .
  • M 1 is defined as for a compound of Formula I
  • M 1 can be a 5-benzoxazolyl or a 6-benzoxazolyl moiety, including but not limited to those M 1 moieties disclosed herein.
  • M 2 is a moiety which is synthetically transformed to form M 1 , after the M 2 moiety has been coupled to the bicyclic core of the compound of Formula N-1.
  • a compound of Formula N-1 may be synthesized as shown in Scheme N-1.
  • a compound of Formula N-1 is reacted with a trialkyl borate or a boronic acid derivative to produce a compound of Formula N-1.
  • the reaction is typically run a solvent such as dioxane or tetrahydrofuran.
  • the trialkyl borate includes but is not limited to triisopropyl borate and the boronic acid derivative includes but is not limited to bis(pinacolato)diboron.
  • a base such as n-butyllithium is first added to the compound of Formula N-3 to generate an anion, prior to the addition of the borate.
  • a boronic acid derivative such as bis(pinacolato)diboron
  • a palladium catalyst and a base is used.
  • Typical palladium catalysts include but is not limited to palladium chloride (diphenylphosphino)ferrocene).
  • a suitable base includes but is not limited to potassium acetate.
  • a compound of Formula N-3 suitable for use in Scheme N-1 is a compound wherein T 2 is halo or another leaving group such as mesylate, tosylate, or triflate.
  • X 1 , X 2 , X 3 , R 1 , R 31 , and R 32 of the compound of Formula N-3 is as defined for a compound of Formula I-A.
  • a compound of Formula A, B, B′, B′′, C, C′′, D, E, E′′, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1′′, N-3′′, 3-1′′, 3-3′′, 3-4′′, 3-5′′, 3-6′′, N-1′′, or N-3′′ is provided as its salt, including but not limited to hydrochloride, acetate, formate, nitrate, sulfate, and boronate.
  • a palladium compound including but not limited to palladium chloride (diphenylphosphino)ferrocene) and palladium tetrakis (triphenylphosphine), is used in the synthesis of a compound of Formula A, B, B′, B′′, C, C′′, D, E, E′′, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1′′, N-3′′, 3-1′′, 3-3′′, 3-4′′, 3-5′′, 3-6′′, N-1′′, or N-3′′.
  • palladium chloride diphenylphosphino
  • triphenylphosphine palladium tetrakis
  • a palladium compound When a palladium compound is present in the synthesis of a compound of Formula A, B, B′, B′′, C, C′′, D, E, E′′, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1′′, N-3′′, 3-1′′, 3-3′′, 3-4′′, 3-5′′, 3-6′′, N-1′′, or N-3′′, it is present in an amount ranging from about 0.005 molar equivalents to about 0.5 molar equivalents, from about 0.05 molar equivalents to about 0.20 molar equivalents, from about 0.05 molar equivalents to about 0.25 molar equivalents, from about 0.07 molar equivalents to about 0.15 molar equivalents, or about 0.8 molar equivalents to about 0.1 molar equivalents of the compound of Formula A, B, B′, B′′, C, D, E, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1, or N-3.
  • a palladium compound including but not limited to palladium chloride (diphenylphosphino)ferrocene) and palladium tetrakis (triphenylphosphine) is present in the synthesis of a compound of Formula A, B, B′, B′′, C, C′′, D, E, E′′, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1′′, N-3′′, 3-1′′, 3-3′′, 3-4′′, 3-5′′, 3-6′′, N-1′′, or N-3′′ in about 0.07, about 0.08, about 0.09, about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, or about 0.15 molar equivalents of a starting material of Formula A, B, B′, B′′, C, C′′, D, E, E′′, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1′′, N-3′′, 3-1′′, 3-3′′, 3-4′′, 3-5′′
  • the R G2 moiety is removed, using suitable methods, at any point desired, whereupon the compound of Formula C, 3-1,3-3, 3-4,3-5, 3-6, A-2,4-1, 4-2, N-1 or N-3 has a R 31 hydrogen replacing the R G2 moiety on the amino moiety.
  • This transformation is specifically illustrated for the conversion of a compound of Formula C′′ to a compound of C (i.e., as in Step 4 of Scheme E′) and for the conversion of a compound of Formula 3-6′′ to a compound of Formula 3-6 (i.e., as in Step 5 of Scheme D′).
  • This illustration is in no way limiting as to the choice of steps wherein a compound comprising a NR 31 R G2 moiety may be converted to a compound comprising a NR 31 R 32 moiety wherein the R 32 moiety is hydrogen.
  • the invention encompasses methods of synthesis of the compounds of A, B, B′, B′′, C, E, 3-1,3-2, 3-3,3-4, 3-5, 3-6, N-1 or N-3, wherein one or more of M, M 1 , or R 1 has a protecting group present during one or more steps of the synthesis.
  • Protecting groups suitable for use for a M, M 1 , or R 1 moiety are well known in the art, as well as the methods of incorporation and removal, and the reagents suitable for such transformations.
  • Reaction Schemes O, P and Q illustrate methods of synthesis of borane reagents useful in preparing intermediates of use in synthesis of the compounds of the invention as described in Reaction Schemes 1 and 2 above, to introduce benzothiazolyl substituents.
  • a compound of Formula O-1 is treated with, for example, nitric acid to produce a compound of Formula O-2.
  • the compound of Formula O-2 is treated with a reducing agent such as stannous chloride to produce a compound of Formula O-3.
  • the compound of O-3 is treated with sodium nitrate in acide and cupric bromide to produce a compound of Formula O-4.
  • the compound of O-4 is treated a base such as butyl lithium and boron tris-isopropoxide to produce a compound of Formula O-5.
  • a compound of Formula P-1 is treated with, for example, potassium thiocyanate and bromine in acetic acid to produce a compound of Formula P-2.
  • the compound of Formula P-2 is treated with an acetylating reagent such as acetyl chloride to produce a compound of Formula P-3.
  • the compound of P-3 is reacted with, for example, bis(pinacolato)diboron (compound P-4) in the presence of a catalyst such as palladium chloride to produce a compound of Formula P-5.
  • the compound of Formula P-2 is reacted with, for example, methyl carbamic acid chloride to produce a compound of Formula Q-1.
  • the compound of Formula Q-1 is reacted with bis(pinacolato)diboron (compound P-4) in the presence of a catalyst such as Pd 2 (dba) 3 , 2-chlorohexylphosphino-2,4,6-triisopropylbiphenyl, a base suchy as potassium acetate, to produce the compound of Formula Q-2.
  • Illustrative compounds of the invention include those of subclass 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, or 16b, where the substituents R 1 , X 1 , and V are as described below.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is H and X 1 is N
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is CH 3 and X 1 is N
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is Et and X 1 is N
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is iPr and X 1 is N
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is iPr, X 1 is N, and V is NH 2 .
  • R 1 is iPr, X 1 is N, and V is NHCOMe.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is cyclopentyl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenyl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is pyridin-2-yl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is N-methylaminocyclohex-4-yl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is tert-butyl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is 1-cyano-but-4-yl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is 1-cyano-prop-3-yl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is 3-azetidinyl and X 1 is CH
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • V is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.
  • R 1 is phenylamino, benzyl, phenyl, NHMe, NH 2 , NHEt, NHCOH, NHCOMe, NHCOEt, NHCOiPr, NHCOOMe, CONHMe, or NHSO 2 Me.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/683,967 2011-11-23 2012-11-21 Enhanced treatment regimens using mtor inhibitors Abandoned US20130209543A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/683,967 US20130209543A1 (en) 2011-11-23 2012-11-21 Enhanced treatment regimens using mtor inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563516P 2011-11-23 2011-11-23
US13/683,967 US20130209543A1 (en) 2011-11-23 2012-11-21 Enhanced treatment regimens using mtor inhibitors

Publications (1)

Publication Number Publication Date
US20130209543A1 true US20130209543A1 (en) 2013-08-15

Family

ID=48470426

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/683,967 Abandoned US20130209543A1 (en) 2011-11-23 2012-11-21 Enhanced treatment regimens using mtor inhibitors
US14/360,267 Active US9174994B2 (en) 2011-11-23 2012-11-21 Enhanced treatment regimens using mTor inhibitors
US14/884,120 Active US9669032B2 (en) 2011-11-23 2015-10-15 Enhanced treatment regimens using mTOR inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/360,267 Active US9174994B2 (en) 2011-11-23 2012-11-21 Enhanced treatment regimens using mTor inhibitors
US14/884,120 Active US9669032B2 (en) 2011-11-23 2015-10-15 Enhanced treatment regimens using mTOR inhibitors

Country Status (7)

Country Link
US (3) US20130209543A1 (enrdf_load_stackoverflow)
EP (1) EP2793893A4 (enrdf_load_stackoverflow)
JP (1) JP6130391B2 (enrdf_load_stackoverflow)
CN (1) CN104363914A (enrdf_load_stackoverflow)
CA (1) CA2856803A1 (enrdf_load_stackoverflow)
HK (1) HK1203378A1 (enrdf_load_stackoverflow)
WO (1) WO2013078440A2 (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015050957A3 (en) * 2013-10-02 2015-11-12 Oklahoma Medical Research Foundation Treatments for systemic lupus erythematosus
US20160287601A1 (en) * 2013-10-03 2016-10-06 Millennium Pharmaceuticals, Inc. Enhanced treatment regimens using pi3k inhibitors
WO2024249380A3 (en) * 2023-05-26 2025-04-03 University Of Vermont And State Agricultural College 1h-pyrazolo[3,4-d]pyrimidin-4-amines as anti-infectious agents

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203378A1 (en) * 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2015148615A1 (en) * 2014-03-26 2015-10-01 Millennium Pharmaceuticals, Inc. Treatment of bronchiolitis obliterans syndrome
WO2015148626A1 (en) * 2014-03-26 2015-10-01 Millennium Pharmaceuticals, Inc. Treatment of fibrotic disorders
WO2015148623A1 (en) * 2014-03-26 2015-10-01 Millennium Pharmaceuticals, Inc. Treatment of fibrotic respiratory disorders
CA2985791A1 (en) * 2015-05-13 2016-11-17 Memorial Sloan Kettering Cancer Center Macropinocytosis in cancer
KR102744951B1 (ko) 2016-03-28 2024-12-23 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
KR20240142568A (ko) 2016-04-15 2024-09-30 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
JP2022500384A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3898637B1 (en) 2018-12-18 2024-11-20 Novartis AG Rapamycin derivatives
CA3134653A1 (en) 2019-03-26 2020-10-01 Novartis Ag Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof
US20210205322A1 (en) * 2020-01-08 2021-07-08 Albert Einstein College Of Medicine Rictor-targeted therapy in the management of brain metastases
WO2021247969A1 (en) 2020-06-05 2021-12-09 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116515988A (zh) * 2023-03-21 2023-08-01 中南大学湘雅二医院 用于评估长期使用糖皮质激素后t淋巴细胞功能的标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
CS277070B6 (en) 1989-12-22 1992-11-18 Adamovske Strojirny Np Device for the control of printing pressures
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
FI944549A7 (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
MX9301942A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Derivados de ciclohexan-ilideno novedosos.
JP3192424B2 (ja) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5759787A (en) 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CZ20004868A3 (cs) 1998-06-23 2001-08-15 Glaxo Group Limited 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolové deriváty, způsob jejich přípravy a fármaceutické prostředky, které je obsahují
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
KR100563395B1 (ko) 1998-06-30 2006-03-23 다우 글로벌 테크놀로지스 인크. 중합체 폴리올 및 이의 제조방법
CA2347512C (en) 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
IL145742A0 (en) 1999-05-04 2002-07-25 Schering Corp Piperidine derivatives useful as ccr5 antagonists
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
JP5557974B2 (ja) 1999-10-07 2014-07-23 アグイラ−コルドバ，カルロス，エストアルド 遺伝子治療による固体腫瘍及び転移の治療方法
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
TR200400420T4 (tr) 2000-06-27 2004-03-22 Laboratorios S.A.L.V.A.T., S.A. Arilalkilaminlerden türetilmiş karbamatlar.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
CA2634715A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy}-11.beta.-hydroxy-16.alpha-methyl-3-oxo-androsta-1,4-diene-17.beta.carbothioic acids-fluoromethyl ester as an anti-inflammatory agent
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US20030165902A1 (en) * 2000-09-29 2003-09-04 Bieglecki Karyn M. Haplotypes of the F2R gene
US6423546B1 (en) * 2000-11-02 2002-07-23 Miller Brewing Company Monoclonal antibodies for assaying lipid transfer proteins
WO2002063046A1 (en) * 2000-11-09 2002-08-15 Genaissance Pharmaceuticals, Inc. Haplotypes of the tacr2 gene
WO2002055534A2 (en) * 2000-11-10 2002-07-18 Genaissance Pharmaceuticals Haplotypes of the f2rli gene
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
UA75626C2 (en) 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
PA8546101A1 (es) 2001-05-25 2003-12-10 Pfizer Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
WO2002100879A1 (en) 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
EP2327766B1 (en) 2001-06-21 2015-12-02 BASF Enzymes LLC Nitrilases
EP1438309A1 (en) 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
UA76571C2 (en) 2001-12-20 2006-08-15 Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003086408A1 (en) 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
US7153968B2 (en) 2002-06-25 2006-12-26 Merck Frosst Canada, Ltd. 8-(biaryl)quinoline PDE4 inhibitors
EP1519922A1 (en) 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DK1521733T3 (da) 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
PL372926A1 (en) 2002-08-10 2005-08-08 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
CN1688544A (zh) 2002-08-23 2005-10-26 兰贝克赛实验室有限公司 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
DE60311662T2 (de) 2002-08-29 2007-10-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
JPWO2004026873A1 (ja) 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
US20070212707A1 (en) 2004-07-23 2007-09-13 Ge Healthcare Uk Limited Cell cycle markers
PL1951724T3 (pl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc SKONDENSOWANE BICYKLICZNE INHIBITORY mTOR
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
AU2010313152A1 (en) * 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6268097B2 (ja) * 2011-11-11 2018-01-24 デューク・ユニヴァーシティ 固形腫瘍治療のための併用薬物療法
HK1203378A1 (en) * 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Boulay et al ("Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells." Cancer Res 2004;64:252-261). *
Han et al ("Aberrant Hyperactivation of Akt andMammalianTarget of Rapamycin Complex 1Signaling in Sporadic Chordomas." Clin Cancer Res 2009; 15(6):1940-1946). *
Mita et al ("The Role of mTOR Inhibitors for Treatment of Sarcomas." Current Oncology Reports, 2007; 9(4):316-322) *
STN CAS Registry File (1224844-38-5, entered May 21, 2010) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015050957A3 (en) * 2013-10-02 2015-11-12 Oklahoma Medical Research Foundation Treatments for systemic lupus erythematosus
US20160287601A1 (en) * 2013-10-03 2016-10-06 Millennium Pharmaceuticals, Inc. Enhanced treatment regimens using pi3k inhibitors
WO2024249380A3 (en) * 2023-05-26 2025-04-03 University Of Vermont And State Agricultural College 1h-pyrazolo[3,4-d]pyrimidin-4-amines as anti-infectious agents

Also Published As

Publication number Publication date
US20140287031A1 (en) 2014-09-25
CN104363914A (zh) 2015-02-18
US9174994B2 (en) 2015-11-03
EP2793893A2 (en) 2014-10-29
EP2793893A4 (en) 2015-07-08
JP6130391B2 (ja) 2017-05-17
CA2856803A1 (en) 2013-05-30
WO2013078440A2 (en) 2013-05-30
US20160038497A1 (en) 2016-02-11
JP2015500209A (ja) 2015-01-05
US9669032B2 (en) 2017-06-06
WO2013078440A3 (en) 2014-09-25
HK1203378A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
US9669032B2 (en) Enhanced treatment regimens using mTOR inhibitors
US10172858B2 (en) Combination pharmaceutical compositions and uses thereof
US20170209448A1 (en) Treatment regimens using multiple pharmaceutical agents
US9295673B2 (en) Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US20150030588A1 (en) Combination of kinase inhibitors and uses thereof
US20160089371A1 (en) Combination of Kinase Inhibitors and Uses Thereof
WO2012154608A1 (en) Reactive mtor and pi3 kinase inhibitors and uses thereof
US20160287601A1 (en) Enhanced treatment regimens using pi3k inhibitors
WO2012154610A1 (en) Reactive pi3k kinase inhibitors and uses thereof
HK1195793B (en) Combination pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTELLIKINE LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, YI;BUI, LYNNE;MARTIN, MICHAEL;AND OTHERS;SIGNING DATES FROM 20130220 TO 20130320;REEL/FRAME:030197/0004

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CALITHERA BIOSCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA PHARMACEUTICAL COMPANY LIMITED;REEL/FRAME:058288/0933

Effective date: 20211018

AS Assignment

Owner name: FAETH THERAPEUTICS, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CALITHERA BIOSCIENCES, INC.;REEL/FRAME:064156/0744

Effective date: 20230515